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Abstract
The development of suitable in vitro release and diffusion models for contact lens-
based drug delivery may lead to the establishment of in vitro/in vivo correlations. It is
evident that an in vitro model that can reproduce the in vivo results would prevent the
disqualification of an otherwise effective drug delivery material or method due to poor
release results obtained using unsuitable release models. Conversely, it would also aid in
discarding materials with poor properties more efficiently.
An overwhelming amount of research has shown that both drug-soaked silicone hydro-
gel and conventional hydrogel materials are unable to continuously release medication at
therapeutic levels. For example, studies have shown that commercially available contact
lenses can reach extended drug release for up to 24 hours in vivo while significantly shorter
release of the same drug from similar contact lens materials have been observed when
tested using current in vitro release models. The lack of appropriate in vitro release and
diffusion models that are more representative of the physiological conditions in the eye has
provided the impetus for this thesis.
The guiding objective of this thesis was to investigate the several well-recognized pas-
sive/static in vitro ocular drug release models and to introduce novel dynamic in vitro drug
release and diffusion experimental models which may help in explaining the discrepancies
between in vitro and in vivo results.
To effectively recreate the human eye environment in drug delivery studies, the model
needs to consider the limited volume and replenishment of the tear as well as the incorpo-
ration of corneal cells. By comparing three in vitro models (i.e., fixed volume, dynamic,
and cell), the results presented in this thesis aim to offer a robust, reliable and cost effec-
tive testing platform more suitable for assessing the drug releasing capabilities of hydrogel
contact lenses. The release results prove the importance of a dynamic release platform
for testing contact lens materials by identifying interactions between the drug and lens
material that would otherwise be disregarded in the fixed volume model.
While interactions between lens and material are important to consider during devel-
opement and testing in the experimental model, another important parameter to consider
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is drug interactions with cells. Prodrugs such as prostaglandins belong to a large group of
ophthalmic drugs. These compounds are precursors to ophthalmic drugs that are specif-
ically designed to improve the drug residence time in tear film and enhance the drug
uptake by the cell membrane. Within corneal cells, these prodrugs can be metabolized
through different pathways into the active form of the drug, before reaching the targeted
tissue. By using an in vitro cornea model, it was demonstrated that the 24-hour release
of prostaglandin prodrug from a pre-soaked silicone hydrogel was comparable to the daily
dose of that ophthalmic drug delivered as an eye-drop. These results emphasized the
importance of the presence of cells when characterizing the release of drug-delivery mate-
rials, and demonstrated how experimental in vitro models have a significant impact on the
outcomes of testing ophthalmic drug delivery materials.
It was also further hypothesized in this thesis that a cell-based in vitro cornea model
combined with a tear replenishment method to study drug release from a contact lens
is better suited for release studies from ophthalmic materials. Through modeling the
microfluidics of in vivo tear replenishment and using a curved surface to grow cells, a tear
replenishment cell culture system was developed as an in vitro testing platform for ocular
drug delivery. Via continuous replenishment of a tear solution analogue over the surface
of the cell culture model, results from this work demonstrated yet another important role
that a dynamic release model will have in predicting the amount of drug loss from a contact
lens into the tear film/lacrimal system.
Recreating the geometry of the ocular surface as well as the microfluidics of tear replen-
ishment combined with the incorporation of human corneal epithelial cells in this research
proved the potential of drug eluting contact lenses when tested under more realistic con-
ditions. The results and the new models developed in this research project may also help
to explain or provide means to investigate the discrepancies between in vitro and in vivo
studies.
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Chapter 1
Ocular Drug Delivery and the Case
for in Vitro Studies of Corneal Drug
Diffusion
Topical eye-drops are the most common drug delivery method and are used in the treat-
ment of more than 90% of ophthalmic diseases. Eye-drops are characterized as pulse drug
delivery methods whereby they deliver a high concentration of a medication over a short
period of time, followed by a long period of underdosing before the next the eye-drop is
administered. Fig. 1.1 shows the drug concentration profile in the tear film for various
modes of drug delivery. Because of the inefficiency of eye-drops, frequent administration of
drops is necessary, which in turn may lead to the patient’s noncompliance with the therapy.
The relatively short drug residence in the tear film, combined with the essential function
of the cornea as a barrier against xenobiotics, limits the drug absorption to the eye and
results in the low bioavailability of the ophthalmic medications. For example, a study with
latanoprost1 in rabbits showed that only 1% of the ophthalmic medication applied as a
topical droplet was actually taken up into the eye [1].
Soft contact lenses were introduced by Otto Wichterle in 1965 [2, 3], and since then
extensive research has been performed to study their potential as a drug delivery device to
1An ophthalmic drug used to treat glaucoma.
1
replace conventional methods of ocular drug delivery, such as eye-drops and ointments [4].
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Figure 1.1: Tear film drug concentration profile for eye-drop delivery method. A) Drug concentration
in tear film reaches its maximum immediately after the application then drops quickly below the efficacy
threshold due to lacrimation and drainage and absorbance into the cornea, until the application of the next
dose. A late or missed dose results in a prolonged period of insufficient drug levels. An over-administered
dose does not increase drug residence time in the tear film, and may result in a drug concentration above
the toxicity threshold. B) It is believed that drug-soaked contact lenses, as a drug delivery device, release
insufficient amounts of a drug over a short period of time before they are depleted. C) An ideal drug
delivery device to the eye will deliver an adequate amount of medication to the eye, with accurate targeted
dosing at a sustained and controlled fashion to increase bioavailability of the drug. The picture is reprinted
with permission from ref. [5].
To overcome low bioavailability of topical eye-drops and ointments as well as patient
noncompliance, soft contact lenses may be used as drug delivery systems [6]. In a mathe-
matical modeling of the drug diffusion, Li and Chauhan have shown that the drug delivery
efficacy can be improved up to 50% when using soft contact lenses [7]. Although in vivo
studies are required to prove efficacy, in vitro experiments can be used initially to compare
release profiles and identify the most promising candidates for in vivo studies. Drug deliv-
ery studies using contact lenses are generally performed in fixed volume release solutions
in the absence of cells. Human corneal epithelial models have been used extensively to
investigate biocompatibility of various ophthalmic materials [8–10]. Although these exper-
imental models have been used to measure drug permeation, they have not been used as in
vitro models to study drug delivery using a contact lens. This research aimed to investigate
how new experimental models can support the development of drug delivery devices.
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In this thesis, a brief review of the human eye anatomy and glaucoma disease (Sec-
tions 1.1 and 1.2) are covered. In section 1.3, a review of ongoing research in the field
of contact lens based drug delivery is presented. Section 1.4.1 introduces in vitro cornea
constructs and their application in the field of biocompatibility studies of contact lens
materials or other ophthalmic compounds. Finally, the corneal drug permeation/diffusion
studies using excised corneas, as well as cornea constructs, are discussed in section 1.4.1.
At the end of this chapter, a case for the in vitro study of corneal drug diffusion using
contact lenses is made.
1.1 Human Eye Anatomy
The eye is a sophisticated organ surrounded by a bony protective orbit. While extra-
ocular muscles help move and rotate the globe, the ciliary muscles contract and dilate to
adjust the power of the lens to focus on an object. The eye is comprised of several layers
and components and only the structures relevant to this thesis research project will be
introduced.
As shown in Fig. 1.2, the inside of the eye is divided into the anterior and posterior
segments. The posterior segment is located behind the lens and consists of the vitreous,
the posterior sclera, and the retina. The anterior segment (AS) of the eye is in front of the
posterior segment and is further divided into two chambers. The iris, the pigmented part
of the eye, separates the anterior chamber (AC) from the posterior chamber.
The cornea is the window of the eye and with assistance from the tear film is the
strongest refractive entity in the visual system and responsible for two-thirds of the eye’s
focusing power. The cornea, with its five layers, is a strong barrier against bacterial and
viral infections and xenobiotics, such as pathogens, drugs, or small particles. The cornea
in normal conditions is avascular, and nourished through capillaries in the conjunctiva,
episclera, and sclera as well as through the aqueous humor as mentioned above. It is
oxygenated from the atmosphere via the tear film.
Each of the five layers of the cornea has a distinct function. The cornea’s layers, shown
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(a)
(b)
Figure 1.2: a) Segments of the eye, b) Anterior segment of the normal eye. [Images were
retrieved from http://bumseku.hol.es/anatomy-eye, July 2015]
in Fig.1.3, from the outside to the inside are (a) the epithelium, (b) Bowman’s membrane,
(c) the stroma, (d) Descemet’s membrane, and (e) the endothelium. The epithelium, as the
outer-most layer of the cornea, protects the stroma from external injuries and provides a
smooth refractive surface. The epithelium acts as the primary barrier against transcorneal
permeation (illustrated in Fig.1.3(f)&(g)) [11,12]. The center of the epithelium has five to
six layers of cells (also known as stratified epithelium). The single internal layer of basal
cells is responsible for the reproduction of corneal cells. The basal cells migrate to the
front and become part of the two to three layers of the wing cells (polygonal cells). The
wing cells’ migration continues and forms the two layers of flattened epithelial cells before
eventually shedding. The limbus (Fig.1.2b), separating the cornea from the sclera is also
active as an additional source of new epithelial basal cells that migrate into the corneal
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epithelium [13]. The tight junctions present between the superficial cells in the corneal
epithelium prevent the paracellular passage of ophthalmic drugs [14].
Bowman’s membrane is composed of uniform collagen fibers and protects the eye against
microorganisms. Bowman’s membrane has a smooth anterior surface and a less defined
posterior surface that merges into the stroma. The stroma consists of 200 to 250 trans-
parent lamellae and comprises 90% of the entire cornea. The relatively dehydrated state
of the stroma2 and the non-interweaving lamellae laid down at right angles to each other
contribute to the clarity of the stroma. Several cell types, such as keratocytes and fibrob-
lasts, are present in the stroma and play a role in corneal healing and inflammation. The
membrane made up of fine collagen fibers at the posterior side of the stroma is Descemet’s
membrane, and acts as a basement membrane for the endothelium cells. The endothelium
is a flattened honey-comb like single layer of cells. The corneal endothelium acts as a
water pump and contributes to the dehydration of the stroma. The interlocked plasma
membranes of the cells are hydrophobic and provide a barrier against the aqueous humor.
During every blink, the epithelium is bathed with tears, and excess tear is pushed
toward the nose and leaves the eye through a drainage system. The lacrimal system
provides lubrication to the eye along with protecting the eye from trauma and too much
light. The tear film lubricates the cornea and the external globe and also provides oxygen
and nutrients to the cornea. The tear film was previously described as having three layers
(the inner mucin layer, the intermediate aqueous layer, and the outer lipid layer) [13].
Recent research has proposed a new model whereby the tear film lipid layer is composed
of 2 layers. The nonpolar outer layer is in contact with air and retards water evaporation,
but it is thermodynamically unstable as a thin film and collapses into lipid droplets. The
inner polar lipid sublayer is believed to create a substrate to stabilize the upper lipid
sublayer [15].
Due to the hydrophobic nature of the corneal epithelium, the cornea cannot be moist-
ened properly by an aqueous layer. The mucoid (composed of transmembrane glycoproteins
2As a hydrogel, a fully hydrated stroma (100% saturation) would be opaque, the relativly dehydrated
state refers to the saturation of 75%.
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Figure 1.3: Structure of the normal cornea covered with tear film, from top to bottom: (a)
the epithelium, (b) Bowman’s membrane, (c) the stroma, (d) Descemet’s membrane, (e)
the endothelium. (f) transcellular, and (g) paracellular pathways that make up the two
possible transcorneal drug diffusion routes. The picture is reprinted with permission from
ref. [14]
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and mucins) coats the corneal epithelium by binding to the microvilli3 that covers the ep-
ithelial surface, thereby improving hydrophilicity of the epithelium. The aqueous layer is
the major component of the tear film. The outer lipid layer slows the evaporation of the
aqueous component of the tear film.
1.2 Intraocular Pressure and Glaucoma
The space between the cornea and the crystalline lens is filled with aqueous humor, which is
a clear gelatinous fluid similar to blood plasma but lower in proteins. The aqueous humor
provides nutrients to the lens and the cornea and drains metabolites. It is produced by the
ciliary processes in the posterior chamber at a rate of 2 − 2.5µl/min and then circulates
around the pupil into the anterior chamber. The aqueous humor leaves the AC through the
trabecular meshwork (TM) that lies within the angle and then it is collected in the venosus
scler (also called the canal of Schlemm). The angle is the actual anatomical angle created
by the anterior surface of the iris and the arch of the cornea [13]. A cross section of the
angle and ciliary body is shown in Fig. 1.4. The dynamics of aqueous humor production
at the ciliary processes and its drainage through the TM creates the intraocular pressure
(IOP). The normal physiologic balance between the inflow and outflow is reached when
the IOP ranges from 10 to 21 mmHg in adults. People whose IOP stays over 21 mmHg
are more likely to develop glaucoma.
1.2.1 Glaucoma
Glaucoma is a group of disorders that results in irreversible damage to the optic nerve
and loss of vision. Ocular hypertension (OHT), or high intraocular pressure, is considered
a major risk factor for glaucoma, even though in some populations, damage to the optic
nerve occurs despite normal IOP [13]. Age is the next main risk factor for this disease [17].
According to the US centers for disease control and prevention (CDC), more than 60% of
affected people are 50 or above (with the average age of the affected population being 67
3Microscopic cellular membrane protrusions
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Figure 1.4: Anterior chamber of the human eye. Reprinted with permission from ref. [16].
years old). After cataract (39%) and uncorrected refractive errors (18%), glaucoma (10%)
represents the third cause of blindness [18]. When compared to cataracts, the greater
challenge of glaucoma to the public health lies in the fact that the damage caused by this
disease is irreversible [19].
Glaucoma is classified into various primary types: open-angle glaucoma (OAG), angle-
closure glaucoma (ACG), normal-tension glaucoma, and congenital glaucoma with varia-
tions of OAG and ACG. Open-angle glaucoma is the most common form of glaucoma. It
occurs when the trabecular meshwork that drains aqueous humor becomes blocked, leading
to rise in intraocular pressure. Angle-closure glaucoma is less common and the buildup
of fluid is caused by blockage of the angle structure in the anterior chamber. OAG is an
insidious disease with no apparent symptoms for the patient until vision loss appears. In
ACG, the onset is sudden and the symptoms are headache, blurred vision and pain in the
eye [19]. Due to the acute nature of ACG, invasive surgical techniques are often used to
treat the disease. In OAG, the disease is managed by medication to lower the IOP.
Apart from rare cases of congenital glaucoma, the disorder affects the elderly most,
and as the world’s population ages, it is becoming an increasing cause of blindness [19].
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The World Health Organization’s study in 2007 shows that in 2010, the number of people
projected to be blind from open-angle and angle-closure glaucoma would be 8.3 million
out of the 60.5 million suffering from glaucoma. By the year 2020, they predicted that
if no action was taken, this would increase by 30% [17]. The lack of awareness about
glaucoma and its treatment as well as the lack of early diagnosis methods limit prevention
of vision loss. Furthermore, once diagnosed, patient compliance with daily, lifelong use
of eye-drops remains the primary challenge [17]. In a survey of ophthalmologists in the
United States, lack of patient compliance for glaucoma medications was attributed first to
patients’ forgetfulness and second to high costs of medication [20]. Therefore improving
patient compliance can have a major impact on lowering the number of blind people.
Several groups of drugs in the form of topical droplet are used to manage ocular hy-
pertension including prostaglandin F2α analogues, β-blockers, α-agonists, and combina-
tions of the two drug types. Although all of these drugs are used to treat glaucoma, the
prostaglandin F2α analogues are the most effective and first-line standards of care [21].
In 2010, the three prostaglandin F2α analogues, Xalatan (Latanoprost), Lumigan (Bi-
matoprost), and Travatan Z (Travoprost), accounted for 60% of the $2.2 billion generated
revenue of prescription pharmaceuticals to treat OAG [22]. For most patients, glaucoma
medications effectively control IOP to target levels [22]. However, for ACG and OAG, at
least one-third of patients are prescribed two or more medications due to declining efficacy
or inadequate responses to therapy [20,22].
Reports of side effects of using prostaglandins to lower IOP date back to 1965 [23].
Early studies showed that sustained lowering of IOP for more than 24 hours was also
accompanied by severe conjunctival hyperemia and discomfort [24]. Prostaglandins, being
carboxylic acids, also have a limited permeation through the cornea [25]. Therefore, the
more lipophilic esterified or amide prodrugs of the carboxylic acids were developed to better
penetrate through the cornea [26]. Less polar analogues of the prostaglandin F2α such as
Latanoprost, Travoprost, Bimatoprost, and Tafluprost, have shown minimal discomfort
and increased corneal penetration [27].
The esterified or amidified prostaglandin F2α (PGF2α) analogues that are currently
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Figure 1.5: Chemical structure of prostaglandin F2α analogues: a) Latanoprost
b) Travoprost c) Bimatoprost, d) Tafluprost [Retrieved from Cayman Chemical:
www.caymanchem.com, July 2015].
prescribed are presented in Fig. 1.5. All PGF2α analogues have more or less similar phar-
macokinetics [27] and have shown consistently a significant increase in aqueous outflow [21].
PGF2α analogues enhance outflow through mechanisms including changing the shape of
cells, widening the connective tissue-filled spaces and remodeling of the extracellular ma-
trix in the trabecular meshwork [21]. Prostaglandins break into their free-acid form by
hydrolysis facilitated by the enzymes available in corneal cells [28]. Studies have shown
instantaneous hydrolysis of some PGF2α analogues [29–32], while bimatoprost has been
reported to have a slower conversion rate of approximately 25µg/24h [33].
1.3 Ocular Drug Delivery
Ocular drug delivery is either intended to target the ocular surface to manage superficial
conditions such as dry eye, microbial keratitis and conjunctivitis, or to treat intraocular
disorders such as glaucoma, and age-related macular degeneration. Eye-drops, followed by
ointments and gels are still the most common ocular drug delivery method [34]. Eye-drop
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medications are applied topically to the eye in the form of either a solution or suspension
in water [6]. The aqueous eye-drop is rapidly diluted in the tear film and most of it is
drained through the lacrimal system, therefore requiring frequent applications [35].
Studies show that only about 1 to 5% of the applied dose penetrates the cornea [1],
and that due to the relatively fast turnover rate of the aqueous layer of the tear film, the
residence time of hydrophilic medications is around 2 to 5 minutes [36]. The relatively slow
turnover rate of the tear film lipid layer results in increased residence time for lipophilic
drugs, which reside in this layer, and consequently leads to an increased uptake into the eye.
The purpose of topical ophthalmic drug delivery devices is to deliver an adequate amount of
medication to the anterior segment of the eye, with accurate targeted dosing at a sustained
and controlled rate to increase bioavailability of the drug. Several commercial ocular
delivery devices are currently available, including surface-located inserts [37], degradable
or non-degradable implants [38], and in situ forming gels [39]. Despite almost 50 years
of research being conducted on the potential use of soft contact lenses to deliver topical
ophthalmic drugs [4], no drug delivery contact lens has yet been commercialized [7].
1.3.1 Contact Lens Drug Uptake Mechanism
When it comes to soaking a contact lens in a drug solution, the governing physics can be
described by the partitioning mechanism as long as the drug solution remains diluted and
uptake is to the bulk of the contact lens material as opposed to adsorbed on the surface
of the lens. Beyond the dilute solution region, the solute-solute interactions can not be
neglected and therefore the partition law may not apply. The Partition Law states that:
“If a third substance be added to a system of two immiscible liquids, the added component
will tend to distribute itself between the two solvents until, at equilibrium, the ratio of
the concentrations (or mole fractions) of the distributed substance will attain a certain
value” [40].
This ratio, as shown in Fig. 1.6, is generally insensitive to pressure, temperature and
concentration changes. The partition law is a phenomenon that is observed from measure-
ments and applies to two immiscible liquids but it is not limited to immiscible liquids [41].
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Ci = [X]I
Cii = [X]II
P = [X]I[X]II
Figure 1.6: Partition ratio of the compound X in solutes I and II is the ratio of that
compound’s concentration in the solutes; figure adapted from ref. [40]
A hydrogel contact lens is not a liquid, but due to its high water content, it holds proper-
ties of a liquid solvent4. Therefore, it is assumed that the partition law applies and for a
drug soluble in water and a soft contact lens, the partition ratio would reach a constant
value at the equilibrium. If a drug is ionic, associates or dissociates in a certain solvent,
the ”distribution ratio” can be used instead [40]. Also in case of a self-associating drug
or a drug that can be adsorbed on the surface of a contact lens due to hydrodynamic5
attributes, modifications should be made to the mathematical uptake model to encompass
all uptake venues.
A hydrogel contact lens (silicone and conventional) mainly consists of cross-linked
polymers/co-polymers and water. Fig. 1.7 illustrates a simplified representation of a hy-
drogel contact lens material soaking in a drug solution. It can be contemplated that the
larger concentration gradient in the solution drives the drug into the aqueous component of
the hydrogel. It has been suggested that the drug may then interact with the polymer ma-
trix through charge-charge, charge-dipole, hydrogen bonding, weaker polar or hydrophobic
mechanisms [43]. The amount of the drug dissolved in the water content of the polymer
can be calculated at the equilibrium using the drug solubility in aqueous solution. It has
been shown that the ratio of dissolved drug in water content to the total drug taken up
by the lens is negligible for relatively hydrophobic drugs (i.e., partition ratio, P > 0).
Therefore, the contact lens material could be considered a homogeneous material where
4Soft contact lenses are highly saturated polymer networks which may contain up to 75% of water.
Assuming the contact lens material as a solvent, immiscible in water, is commonly used in contact lens
research.
5hydrodynamic refers to all non-lipophilic and interactive modes with the contact lens surface (e.g.
hydrophilic, ionic, and van der Waals types of interaction) [42]
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Figure 1.7: Illustration of the drug uptake into a soft contact lens in drug solution; a)
before equilibrium is reached, b) after equilibrium is reached in case of a drug with large
partition ratio vs. c) a drug with small partition ratio. Lighter shade (left of the dashed
line) represents the aqueous component of the contact lens material.
there is a partition ratio between the contact lens material and the soaking solution for a
certain hydrophobic drug or compound. For hydrophilic species, it would be important to
adjust for the fraction of the drug held in the aqueous portion of the hydrogel.
It can be concluded that for drugs with high partition ratio (hydrophobic drugs), as
illustrated in Fig. 1.7(b), a significant amount of drug will be taken up through association
with the polymer network of the hydrogel. Also, in the case of a significantly smaller
partition ratio, as shown in Fig. 1.7(c), although most of the drug may or may not be taken
up by the hydrogel, a greater portion of the drug would remain in the aqueous solution
(represented by both the solvent and the water content of the contact lens material).
The drug uptake through adsorption on the surface of the hydrogel, in case of a sur-
face treated contact lenses, will be affected by the surface charge and the hydrodynamic
attributes. The other important factor would be the size of the drug molecule. Due to
the compact structure of the contact lens polymer network, larger drug molecules, such as
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polypeptides or proteins, may not be loaded effectively by simply soaking the hydrogel in
the drug solution. Therefore, loading a drug into a contact lens through soaking, as the
most likely method to be used in the commercial production of therapeutic contact lenses,
would reasonably be limited to low molecular weight drugs (< 500Da).
Furthermore in an extensive study of ophthalmological drugs loaded into commercially
available contact lenses, Tabuchi et al. have shown that the hydrophobic interactions of
the actives (i.e., drugs or other compounds) with the contact lens material is the primary
governing factor in the adsorption of those compounds [44]. During the soaking of the
contact lens in a drug solution, drugs that showed higher affinity toward the contact lens
material adsorbed significantly more on and into contact lens material compared to hy-
drophilic drugs [44]. This is also consistent with the observations of Mahomed et al. with
hydrophobic surrogate drugs (see below, [43,45]).
When considering drug uptake, the effects of the edge in a drug eluting polymeric de-
vice can be ignored, if the aspect ratio of the polymer diameter is greater than 10 times the
thickness [46]. However, the thickness of the lens will affect the total volume and thus the
uptake. Contact lens thickness varies depending on the prescription. Therefore, to elimi-
nate variations in total lens material volume, it is necessary to maintain the prescription
the same in drug release experiments.
1.3.2 In Vitro Contact Lens Drug Release Models
In pharmaceutical research, solute release from polymeric devices is most often performed
under perfect sink conditions. Under such conditions, the fractional solute release ratio
is defined as Mt/M∞, where Mt is the amount of drug released at time t, and M∞ is the
total drug release, or drug release as time reaches infinity. It has been shown that this
ratio can be approximated by a simple exponential relation Mt/M∞ = ktn, where k is a
constant, and 0.43 < n < 0.5 depending on the geometry of the polymeric device (i.e.,
slab, disk, cylinder, or sphere) [47]. The sink condition is maintained by testing the drug
releasing device in 500mL to 1000mL of solution. The concentration of the solute in the
release media should remain below 10% of its solubility to retain near sink conditions. The
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direct implication of infinite sink assumption is that the most of the drug if not all will
be released from the contact lens, since the concentration gradient will drive the drug out
of the polymer network. While drug releasing contact lenses are generally tested similarly
to a drug eluting polymeric devices under sink conditions, it is clear that this assumption
is far from the limited tear volume conditions in the front of the eye. The fractional
solute release ratio provides relevant information about certain characteristics of the drug
releasing polymeric devices and enables comparison of different polymers and their drug
releasing capabilities. However, the lack of sink condition in the eye, both in terms of the
volume of the release solution and the assumption of drug concentrations well below drug
solubility, limits drawing conclusions on actual ocular drug release profile based on those
characteristics.
Drug releasing ophthalmic materials have used a range of experimental models to study
the drug-polymer interactions and efficacy of the drug release. Over 80% of drug release
studies from contact lens materials has been conducted in passive release models. These
models use less than 10 mL volume of deionized (DI) water, or Phosphate Buffered Saline
(PBS), creating a small sink condition [48]. In these studies, the drug-eluting contact lens
material is placed in a vial with a specific volume of the release solution, and either samples
are collected from the solution at various time points or the entire solution is refreshed to
maintain the sink condition. In the fixed volume release studies, parameters such as the
release medium and its volume, as well as mixing condition are important [49].
Passive release studies of ocular drug delivery devices have given rise to the popular
belief that simple “soaking” of a contact lens in a topical drug solution may be insufficient
for adequate elution on the ocular surface. Therefore, such a method has been considered to
have a low potential for success [49–51]. Thus, a variety of research efforts are attempting
to increase the drug uptake and/or release rates. These have included prolonged (up to
2 weeks) soaking [52], soaking the lenses in super-critical drug solutions [53], soaking the
dehydrated contact lenses in drug solutions [54], molecular imprinting [55–57], and using
vitamin E as a barrier to decrease diffusion of the drugs [52, 58, 59]. To improve drug
release from contact lens materials, two approaches have been used. First, attempts have
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been made to add diffusion barriers such as vitamin E into the lens as well as molecular
imprinting which successfully slowed down release of the loaded drug [52,59]. In a second
approach to improve release, researchers have attempted to increase the amount of drug
uptake, which has appeared to have minimal to no effect on the elution time and release
kinetics [49].
Due to their low cost and ease of quantification, the use of ophthalmic fluorescent
dyes as surrogate drugs has been recognized as an appropriate approach when designing
high-throughput assays to characterize and identify desired polymeric compounds for drug
delivery applications [60]. In a series of publications, Mahomed et al. investigated the
interactions of hydrophilic and hydrophobic surrogate drugs with commercial contact lens
materials in order to identify the role of physicochemical properties (such as molecular
weight, charge, partition coefficients) and the influence of parameters such as uptake solu-
tion concentration and pH [43,45]. They have shown that the extraction media volume and
the trigger mechanisms such as mechanical agitation also play a role in the amount of the
drug released [45]. Mahomed et al. demonstrated that under passive release conditions for
the range of surrogate drugs and contact lens materials studied, the release kinetic main-
tained a first order release kinetics, which followed the Fickian diffusional release6 from a
thin slab of polymer [43]. This first order release kinetic results in an initial burst of drug,
followed by a slow release. Unfortunately, this does not meet the requirement of the ocular
drug delivery devices, which is to achieve a zero-order release to deliver a sustained and
adequate amount of the drug to the eye.
The effects of temperature, release volume, and mixing condition has been studied ex-
tensively by Tieppo et al. Using four ophthalmic drugs loaded on synthesized conventional
and silicone hydrogel materials, these studies showed that poor mixing conditions as well
as inadequate release media volume will affect the release kinetics dramatically: the equi-
librium is reached significantly faster, thus reducing the continued release of the retained
drug in the contact lens matrix [48].
It has become evident from the studies by Tieppo et al. and Mahomed et al. that
6Diffusive flux is proportional to the concentration gradient under steady state condition, J = −D ∂C∂x .
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Figure 1.8: Schematic of an experimental microfluidic set-up for contact lens drug delivery
evaluation reproducing the physiological flow rate of the eye. The picture is reprinted with
permission from ref. [46]
the drug release profile can be significantly affected by the experimental set-up [43,45,48].
Before this was actually recognized, an early attempt by Ali et al. using physiological
flow conditions (3µL/min) suggested that the release rate of ophthalmic drugs could be
slower and more linear when compared to the small sink model often used to study release
profiles [61]. As a continuation of that work, Tieppo et al. introduced a microfluidic
device, as depicted in Fig. 1.8, which could provide a more representative release model of
the ocular environment by reproducing physiological flow rates to study the release from
ophthalmic drug delivery materials. The results of this study showed a zero-order release for
approximately 48 hours [46]. In the physiological flow model, an overall reduced release was
also observed which was attributed to the concentration boundary layer resulting from the
limited liquid volume surrounding the contact lens material [46]. However, considering the
material used for the microfluidic device was polydimethylsiloxane (PDMS), also a major
component of silicone hydrogel contact lenses, adsorption of the drug into the chamber
material may also have contributed to the reduced release.
In two recent studies, Phan et al. and Bajgrowicz et al. used a two piece design to
model the geometric and microfluidic conditions of the ocular surface [62,63]. This design
allows vertical placement of the contact lens on a convex piece, modeling the cornea, and
creating a cavity for the flow of the release media by encasing the contact lens between
a secondary concave piece, modeling the eyelid (see Fig. 1.9). The release results using
the model showed a sustained release over time when compared to the burst release of the
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Figure 1.9: Schematic of a two-piece microfluidic ocular surface model for contact lens
drug delivery evaluation reproducing the geometry and physiological flow rate of the eye.
The picture is reprinted with permission from ref. [62].
tested drug in a passive fixed volume release model. The two-piece design in this model
allows incorporation of mechanical stimulation by means of moving the eyelid piece.
There has also been efforts to produce artificial tear solution by adding proteins such as
albumin, lysozyme, mucin, lactoferin, immunoglobulin G, and various lipids to a buffered
solution [64]. Artificial tear solutions have been used to investigate the deposition of tear
film components on ophthalmic materials [65]. The use of artificial tear solution in drug
release studies from contact lens materials may prove valuable due to the barrier effect as
a result of protein deposition on contact lens. However, there are no current reports of
using such solution in drug release studies, most likely due to the added complexity to the
drug release measurements.
While in the past few years new experimental models have been introduced to study
mechanisms of release from drug delivery devices under dynamic conditions, these models
do not take the drug interactions with the cells into consideration.
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1.4 Drug Diffusion through the Cornea
The conjunctiva and the sclera have been reported to play a small role in drug delivery
to the anterior chamber [13]. Therefore, the cornea remains the most important tissue
to study in drug interactions with the ocular surface [14, 66]. As mentioned previously,
the human cornea consists of three main cellular layers, the epithelium, the fibroblastic
stroma, and the endothelium. The primary drug permeation route to the front of the eye
is through transcorneal pathways, which includes paracellular and transcellular pathways
[25]. The lipid bilayer cell membrane retards the permeation of hydrophilic compounds.
The paracellular passage (the pathway through gaps between cells) is the main pathway
for hydrophilic actives [14]: the corneal epithelium and the tight junctions control the
transport of the hydrophilic drugs through the cornea (see Fig. 1.3) [67–69]. The corneal
epithelium is considered to be the rate-limiting factor in the transcorneal permeation of
most ophthalmic drugs [12], especially for hydrophilic drugs [67, 68]. The transcellular
passage is the major pathway for hydrophobic compounds. Therefore, the uptake of a
topically applied hydrophobic drug in the cornea is dependent on the lipophilicity of the
compound. However, the hydrophilic nature of the stroma will generate a resistance toward
the permeation of hydrophobic drugs. Through expression of membrane transporters and
specific enzymes present in the epithelial cells, the cornea is thought to be involved in
metabolism and transport of prodrugs and their active forms [29–32,70]. In a recent study,
Kidron et al used a statistical model to identify correlation of the corneal permeability of
58 ophthalmic drugs with parameters such as molecular weight, molecular volume, polar
surface area (PSA), number of hydrogen bond donors (HBD), number of hydrogen bond
acceptors (HBA), total number of putative hydrogen bond (HBtot), partition ratio as well
as distribution ratio at various pH levels (LogP & LogD). The results of this study challenge
the role that membrane transporters are believed to play in ophthalmic drug permeation
[71].
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1.4.1 In Vitro Cornea Models
With the increasing interest in using contact lens as drug delivery devices and the desire to
understand the complex interactions between lens cleaning solutions and lenses, there has
been an increasing need for in vitro cornea models that can better assess biocompatibility
and identify promising candidates for animal study. While in vivo studies enable the
assessment within the physiological systems, they are often very costly, involve the sacrifice
of animals, and may be difficult to interpret given both interspecies variation and animal-
to-animal inconsistency [72–75]. A classic failure of animal models has been that the
bioavailability of oral drugs determined from animal data may not be extrapolated to
human [76].
Human cornea in vitro models may offer a cost effective and more standardizable sub-
stitute [66]. Reconstructed cornea equivalents as well as cell culture models of the human
corneal epithelium (HCE) are being used to study in vitro ocular toxicity and permeabil-
ity [77–82]. Reconstructed cornea equivalents which consist of all layers are expected to
correlate well with in vivo results [25]. However, it is recognized that the epithelium acts
as the primary barrier against transcorneal permeation which can in turn be correlated to
the electrical resistance of the cornea. The epithelium is responsible for 99% of corneal
electrical resistance [83, 84]. Thus, the epithelium alone can also be considered for an in
vitro model as it would reduce cell culture cost and time, and allow for higher throughput
testing of biomaterial interaction and drug permeation [80]. Primary corneal epithelial cells
can be isolated from human donor corneas. The isolation protocol is lengthy and contam-
ination with other cells may occur. Primary cells also have a limited lifespan and corneal
epithelial cells can only be cultured for up to five passages prior to changes in cell phe-
notype. While primary corneal epithelial cells are commercially available (which reduces
the risk of contamination), the cost associated with using primary cells is significant due
to their limited lifespan. Due to these difficulties with primary cultures of human corneal
epithelial cells (HCEC), two cell lines with properties similar to normal corneal epithelial
cells were established [85, 86]. Both simian virus 40 (SV-40) immortalized HCEC and hu-
man corneal epithelial cells transfected with human papillomavirus (HPV) 16 E6/E7 genes
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7 can achieve an extended lifespan. They can also be grown into a stratified cornea model
that can form tight junctions similar to the human corneal epithelium. While monolayers
of these cell lines have been used to study toxicity and biocompatibility [78,87,88], strati-
fied cultures have been shown to better mimic the human cornea [89]. The stratification8
is achieved through the creation of an air-liquid interface which promotes the formation
of tight-junctions and is an essential characteristic of the cornea’s barrier function [90].
During stratification, up to five layers of cells have been observed [78].
The main challenges in developing in vitro models lie in being able to replicate the
relevant factors of the in vivo environment and in understanding the limitations of the
model’s capabilities. Generally, in vitro studies using monolayers of corneal epithelial cells
show lower tolerance compared to in vivo studies [89]. A human eye holds approximately
7 − 30µL of tear film with a turnover rate of 0.5 − 2.2µL/min [84, 91–94]. Spontaneous
blinking happens at the rate of 6-15 times/min and helps to mechanically spread the tear
film evenly across the ocular surface and to remove any foreign objects in contact with
the eye [84]. Maintaining an air-liquid interface in the in vitro cornea models helps cell
cultures to retain their epithelial characteristics. However, it is also necessary to keep the
surface moist or the corneal epithelium will undergo an abnormal, squamous (skin-like),
differentiation [82].
1.4.2 In Vitro Cornea Models for Corneal Drug Diffusion
In vitro cell models with different levels of complexity are used in the evaluation of drug
delivery systems as well as new drugs [95]. However, the use of HCEC models has been
limited to exploring the effects of metabolic conversion and active drug transport in corneal
permeability assessments [25,81,96–98]. In these experiments, permeability of cornea con-
structs are studied in static diffusion cells (Franz cells) or dynamic diffusion cells (Bronaugh
cells) as shown in Fig.1.10. In a Franz cell, the drug solution diffuses from the donor cham-
7Epithelial cells infected with an amphotropic recombinant retrovirus containing HPV-16 E6/E7 genes
to extend their lifespan.
8The process of cells growing in layers, expressing certain phenotypes based on their position in the
multilayer structure.
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Donor Chamber
Membrane,
Excised Cornea Tissue,
Cornea Model
Sampling Port
Receptor Chamber
Stir Bar
(A) (B)
Inlet
Outlet
Figure 1.10: Existing in vitro cornea constructs are used to assess permeability of the tissue
using A) static (Franz) diffusion cell, and B) dynamic (Bronaugh) diffusion cell. The drug
solution diffuses from the donor chamber through the membrane into the receptor chamber
where drug samples are collected at regular intervals. In a Bronaugh cell, the flow-through
system maintains sink conditions and allows continuous collection of samples.
ber through the excised corneal tissue or in vitro cornea model into the receptor chamber
where samples of the drug are collected. The stirring prevents formation of a stagnant
boundary transfer layer. The diffusion cells were used traditionally with skin models as
well as porcine or rabbit excised cornea to measure permeability of drugs. Later, they were
adopted for cornea constructs [81,96,99–101].
Steady-state permeability experiments enable the understanding of corneal permeabil-
ity, metabolism and active transport. However, it does not account for the rapid elimination
of the eye-drops in the tear film. Understanding the pre-corneal elimination kinetics, as
well as distribution and elimination in the anterior chamber of the eye, when combined
with the permeability studies may lead to the successful simulation of in vivo drug diffusion
through the cornea [102]. Following the measurement of the mentioned parameters, Ranta
et al. mathematically simulated the concentration of timolol in rabbit aqueous humor and
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showed that it matches experimental in vivo results [103].
Currently, to keep a cornea model hydrated, corneal epithelial cells are immersed in
cell culture medium or artificial tear liquid. However, the immersion cell culture system
poorly models the tear replenishment occurring in the human eye via the lacrimal system.
Artificial tear liquids have been utilized to hydrate the surface of corneal epithelial models
by incorporating a moisture holding substance [82]. To simulate blinking, a rocker mech-
anism has also previously been used to generate intermittent flow on top of a cell culture
model [104]. These methods try to address inadequacies of conventional tear replenishment
models, but lack modeling of the physiological environment parameters of the eye such as
constant fluid exchange and limited tear volume.
1.5 A Case for an in Vitro Study of Corneal Drug
Diffusion
In the field of contact lens drug delivery, the inadequacies of current in vitro release models
has limited progress mostly by giving rise to false kinetics of release where the reported
behavior cannot be recreated in the physiologic environment. Table 1.1 compares the
amount of drug released from commercial contact lenses loaded with the same drug and
released in either a fixed volume solution or an in vivo model. The amount of release
and elution time is consistently smaller in the fixed volume versus the in vivo environ-
ments. In the fixed volume conditions, the drug release mechanism is governed by Fickian
diffusion, where concentration gradients generate the driving force and the ratio of the
concentration between the contact lens and the medium is dictated by the partition ratio.
The fixed volume environment does not represent the eye environment where there is a
limited amount of tear liquid with a relatively fast tear turnover. The composition of the
release medium also plays an important role in release studies. While a certain contact lens
material may present optimal release in deionized-water (DI), their performance might be
reduced dramatically in the presence of ions or surfactants [55].
The contribution of enzyme and transport activities such as the esterase activity of
23
T
ab
le
1.
1:
D
ru
g
U
p
ta
ke
an
d
R
el
ea
se
fr
om
C
on
ta
ct
L
en
s
M
at
er
ia
ls
-
R
el
ea
se
M
ed
iu
m
C
om
p
ar
is
on
D
ru
g
M
W
[l
og
P
† ]
C
on
ta
ct
L
en
s
L
oa
d
ed
D
ru
g
R
el
ea
se
d
µ
g
/l
e
n
s
R
el
ea
se
T
im
e
(M
ed
iu
m
)
R
ef
.
A
ce
ta
zo
la
m
id
e
22
2.
24
5
[-
0.
26
]
b
al
afi
lc
on
A
10
0
30
m
in
(5
m
L
sa
li
n
e)
[ 5
3]
sa
u
fl
on
P
W
n
ot
re
p
or
te
d
U
p
to
7.
5h
(i
n
vi
vo
L
ep
or
in
e)
[ 1
05
]
G
en
ta
m
ic
in
47
7.
59
[-
3.
1]
et
afi
lc
on
A
18
6
20
−
30
m
in
(3
m
L
sa
li
n
e)
[ 1
06
]
sa
u
fl
on
85
10
−
30
µ
g
/m
L
U
p
to
2h
(i
n
vi
vo
h
u
m
an
)
[1
07
]
K
et
o
ti
fe
n
30
9.
42
5
[2
.2
]
V
ar
io
u
s
10
5
−
22
7
≤
1h
(2
m
L
sa
li
n
e)
[5
1]
S
iH
y
(1
00
µ
m
th
ic
k
n
es
s)
12
00
µ
g
/m
L
15
-2
4h
(i
n
vi
vo
L
ep
or
in
e)
[1
08
]
L
om
efl
ox
ac
in
35
1.
34
8
[2
.8
]
et
afi
lc
on
A
15
0
1h
[1
09
]
et
afi
lc
on
A
75
0
8h
(i
n
vi
vo
L
ep
or
in
e)
[1
10
]
A
d
ap
te
d
fr
om
re
f.
[4
9]
.
A
ll
co
n
ta
ct
le
n
s
m
at
er
ia
ls
w
er
e
lo
ad
ed
th
ro
u
gh
le
n
s
so
ak
in
d
ru
g
so
lu
ti
o
n
.
T
h
e
a
m
o
u
n
t
o
f
u
p
ta
ke
h
a
s
n
o
t
b
ee
n
re
p
or
te
d
,
h
ow
ev
er
th
e
am
ou
n
t
of
re
le
as
e
va
ri
es
b
et
w
ee
n
in
vi
vo
an
d
fi
x
ed
vo
lu
m
e
re
le
as
e
m
ed
iu
m
.
L
a
rg
er
p
a
rt
it
io
n
ra
ti
o
s
sh
ow
a
la
rg
er
d
iff
er
en
ce
in
re
le
as
e
am
ou
n
t
an
d
el
u
ti
on
ti
m
e.
S
iH
y,
S
il
ic
on
e
H
y
d
ro
ge
l;
†
D
ru
g
in
fo
rm
at
io
n
h
a
s
b
ee
n
re
tr
ie
ve
d
fr
o
m
D
ru
g
B
a
n
k
C
a
n
a
d
a
d
at
ab
as
e
(V
er
si
on
3.
0)
.
P
ar
ti
ti
on
ra
ti
os
ar
e
ex
p
er
im
en
ta
l
va
lu
es
,
an
d
if
n
ot
av
ai
la
b
le
,
th
e
p
re
d
ic
te
d
va
lu
es
o
f
th
e
a
ct
iv
e
in
g
re
d
ie
n
t
a
re
re
p
or
te
d
.
24
the corneal epithelium has been utilized in the design of ophthalmic prodrugs such as
prostaglandin F2α analogues [111]. The lipophilicity as the result of esterification or amidi-
fication in prodrugs facilitates the penetration through the cornea. Hydrolysis of prodrugs
such as prostaglandin analogue into the relatively hydrophilic acid form inside the epithe-
lial cells allows permeation through the stroma [112] and thus, increases the bioavailability
of the active substance in the interior of the eye [113]. Despite extensive studies on the role
of cells in drug permeation and metabolism, their role has largely been ignored in ocular
drug release studies. This could be attributed to the complexity and cost associated with
cell culture models. In the case of prostaglandin F2α analogues as a major group of medi-
cations administered to control the progression of glaucoma, the pharmacokinetics of these
drugs has been extensively studied in vivo [1,72]. However, there has been very limited in
vitro studies of these prodrugs. Moreover, a recent study of a latanoprost eluting contact
lens has shown inconsistent release results between an infinite sink release model and in
vivo (rabbit model) [114]. Such an inconsistency is likely due to the lack of cells in the in
vitro model. Given the cells’ contribution to hydrolysis of latanoprost, the absence of cells
most likely led to inconsistency of the in vitro results.
Given the current state of in vitro models for drug delivery, we may conclude that there
is a need to establish an in vitro cornea model capable of replicating the corneal surface
physiology, and that may help provide better in vitro-in vivo correlations in ocular drug
delivery experiments.
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Chapter 2
Thesis Scope and Hypotheses
In release studies of ophthalmic drug delivery materials, researchers rely on maintaining
sink condition as a means to maximize release and obtain extended release from the contact
lens material. However, the prevailing situation in the eye is the exact opposite, where a
constantly replenished, limited tear volume is retained. To translate release studies into
effective therapies, understanding the cellular and molecular mechanisms of the corneal
tissue and the physiological conditions of the front of the eye is required. The need for
an organotypic model that can better recreate the dynamic microfluidic conditions of the
ocular surface is evident. Also, considering that the primary drug permeation route to the
front of the eye is through transcorneal pathways, it is important to consider the role of
the cornea in drug release studies.
This thesis aims to demonstrate that a cell-based in vitro cornea model combined
with a tear replenishment method would further enhance the study of drug release from
ophthalmic materials targeted toward the front of the eye when compared to the fixed
volume release model.
Given the limitations of current drug release test platforms in recreating the tear re-
plenishment, three goals were pursued. First to design and implement an acellular dynamic
drug release model (DDRM) to recreate the limited tear volume as well as the continuous
tear replenishment of the human eye. This model then was used to investigate the up-
take and release of ophthalmic dyes as surrogates for ophthalmic drugs from commercially
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available contact lenses. Comparisons of the release results obtained using the dynamic
system and conventional models, presented in Chapter 3, provided unique insights into
the release mechanisms that could be used in interpreting discrepancies seen between in
vitro and in vivo results. Using surrogate drugs in an acellular ocular surface model also
allowed investigating interactions of those surrogate drugs with the contact lens materi-
als while offsetting the high cost of ophthalmic drugs and the cost associated with their
measurements.
The cornea, through expression of membrane transporters as well as the presence of
enzymes in the epithelial cells, is involved in metabolism and transport of prodrugs and
their active forms. Another objective of this research was to investigate the role o corneal
epithelial cells in the release and hydrolysis of an ophthalmic prodrug from contact lens
materials. The results, presented in Chapter 4 and published as a journal paper [115],
demonstrated the impact of the presence of live cells on the release mechanisms when
compared to the current acellular models.
While the interactions of the drug and lens material with cells could be studied in static
models such as the immersion in vitro cornea model, the immersion cell culture system
poorly mimics the tear replenishment occurring in the human eye. The lack of tear replen-
ishment in existing in vitro human cornea models limits their ability to accurately simulate
the physiological environment of the human cornea. The third objective of this thesis, the
culminating point in this research, was to design and implement the tear replenishment
system (TRS) as a platform to incorporate a dynamic liquid exchange to the existing in
vitro cornea models. Integration of the tear replenishment system with a well characterized
cell culture system allowed investigation of release of ophthalmic drugs from contact lens
materials in a robust and reliable fashion. The results, presented in Chapter 5, helped to
understand interactions among cells-lens-replenishment parameters that would otherwise
be neglected or dismissed.
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Chapter 3
In Vitro Drug Release from Contact
Lens
3.1 Overview
Since the development of hydrogel contact lenses in 1965, their potential use as a drug
delivery platform has been studied [4]. Different mechanisms have been utilized to load a
drug into a soft contact lens, from soaking them in a drug solution to molecular imprinting,
and carrier mediated release [49]. Because of its simplicity, the drug-soaked contact lens
remains the most popular and practical drug loading mechanism and it is most likely to
be adopted for commercial ophthalmic drug delivery devices. However, previous studies
have suggested that for most ophthalmic drugs and commercially available contact lens
materials, low drug loading and elution times ranging from few minutes to two hours
prevent a prolonged and controlled release.
It was hypothesized that the lack of relevant ocular surface test method for drug release
studies may have contributed to underestimating the drug delivery capabilities of contact
lenses. To test this hypothesis, the study presented in this chapter investigated the uptake
and release of three surrogate drugs from commercially available contact lenses using three
in vitro models. A dynamic drug release model (DDRM) was developed to recreate the
limited tear film volume as well as the continuous tear replenishment that occurs on the
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ocular surface. Using the DDRM, the release of several surrogate drugs from five contact
lens materials was studied. The release results were then compared to a cell based in vitro
cornea model and a conventional small sink release method.
3.2 Design and Implementation of the Dynamic Drug
Release Model
The key purpose of designing the dynamic drug release model is to offer an affordable and
simple release model that sufficiently recreates the release conditions on the surface of the
eye. While a cell model can more closely simulate the eye’s physiological environment, the
requirement of a cell culture facility will be prohibitive for most researchers who focus on
the contact lens material or study the drug-lens interactions. This section focuses on the
design and implementation of a dynamic drug release model with the goal of recreating
the microfluidic conditions of the ocular surface.
3.2.1 Tear Film and Tear Flow, Merits of an Intermittent Fluid
Flow
Blinking in the human eye replenishes the tear film and spreads it over the surface of the
eye. The microfluidic interactions of a drug releasing contact lens with the tear film can be
simplified to a contact lens encased in a chamber with a limited volume of available release
media representing tear film, whereby the release media is replenished intermittently with
the frequency of human blinking representing tear flow. Therefore, an intermittent fluid
flow would be preferable over a continuous laminar flow which is the basis of the design
discussed in this section.
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3.2.2 Design Constraints and Criteria
The key constraints that must be met by the instrument’s design are:
1. providing a suitable surface geometry for contact lenses to be placed (similar to
Byrne’s model [46]),
2. using inert materials that will not interact with the drug or the contact lens material,
3. creating the limited release volume of the tear film accurately and repeatably,
4. delivering a reproducible and adequately small volume of release media intermittently,
5. providing an even distribution of fluid flow over the contact lens material for the
duration of the release,
6. allowing the testing of multiple (i.e., 4) contact lenses at a time,
7. minimizing the loss of the release media through evaporation.
A secondary objective would be to design a cost efficient, open hardware/ open soft-
ware instrument that can be adopted, modified and improved by other researchers for the
purpose of dynamic drug release studies from drug eluting materials.
3.2.3 DDRM Design
The design of the desired microfluidic system can be classified according to the mechanism
that drives the flow, and the approach employed to control the rate of the flow. The liquid
displacement can be generated using the “flow concept”, such is the case with a syringe
pump whereby the liquid movement is the result of the movement of an electromechanical
actuator. The liquid displacement can also be generated using the “effort concept” whereby
a pressure gradient is the driving force behind the movement of the liquid. While both
design concepts have their own merits, using the flow concept in resolving the situation at
hand would require as many syringes as there are test chambers. Using a single syringe
30
would result in an uneven flow rate between the chambers, while using multiple syringes in a
syringe pump would limit the control of the flow independently. Thus, the effort concept is
utilized whereby a pressure gradient is generated through pumping a tear solution analogue
through a pressure relief valve before closing the loop of the system as illustrated in Fig. 3.1.
The controlled flow rate can be achieved by blocking the liquid flow either upstream or
downstream using a series of isolation valves (shut-off valve). The upstream approach, as
would be the case with the syringe pump design, would require the release chamber and the
contact lens to be subjected to atmospheric pressure. The major drawback of such a design
would be the inability to create a uniform flow over the contact lens within the chamber.
On the other hand, limiting the flow downstream would allow a controlled discharge of the
fluid, while maintaining a uniform flow regime within the chamber. The secondary benefit
of a downstream-controlled flow would be the ability of the pressure gradient in removing
air bubbles from the chamber. Eliminating the air bubbles from the release chamber is
necessary to achieve a uniform release from the entire contact lens material, since a bubble
would partly cover the surface of the lens and prevent release from that region of the lens.
Figure 3.1: Design schematic of the dynamic drug release model: the solenoid pump
provides enough back pressure to a series of isolation valves to control the flow rate as well
as the duty cycle of the intermittent flow.
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Tear flow rate in the human eye is approximately 100µL/hr with a tear volume of
7 − 30µL [45, 84, 91–94]. The volume of a contact lens depending on the radius, base
curvature, and the prescription may vary between 140 to 170µL. While the prescription of
the contact lenses used for the experiments can be fixed, not all contact lens manufacturers
produce lenses with the same base curve and radius. To accommodate a wide range of
contact lenses, the curved chamber encasing the contact lenses was designed to have a
cavity volume of 210µL, while the estimated average volume of the contact lenses used for
the experiments was 160µL. The remaining volume is within the same order of magnitude
of the human tear film. The rate of flow can be adjusted by the duty cycle1 of the isolation
valves.
3.2.4 Electromechanical System
The electromechanical components of the designed instruments include: a solenoid oper-
ated micro-pump from Bio-Chem Fluidics™, which is used to pump the tear solution ana-
logue (here PBS) through PTFE2 tubing (Bio-Chem Fluidics, NJ, USA) passing through
a pressure relief valve preset to 20psi before looping back to the release media container
(as illustrated in Fig. 3.2). The two pieces of manifold that encased the lenses and are
used for mounting the solenoid valves were machined out of Polyacrylic and PTFE sheets
because of their excellent inert chemical properties; these parts are depicted in Fig. 3.3a.
Contact lenses are placed in each chamber (the cross section is shown in Fig. 3.3b), and the
release flow aliquots are collected in a 12-well plate (4x6 wells), with each well collecting
the release over a 2h period. The valves, pump, and the motor that moves the 12-well
plate are controlled and driven using a small board computer that is installed inside the
enclosure as depicted in Fig. 3.3c. The enclosed chamber and fluid channels eliminate loss
of release flow through evaporation.
1The percentage of one period where the valve is open.
2Polytetrafluoroethylene, a bio-inert synthetic fluoropolymer with excellent chemical resistance
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Flow outlet
Flow inlet
Cavity chamber encasing the contact lens
Solenoid isolation valve
Figure 3.2: Dynamic Drug Release Model’s cavity design. The tear solution analogue
is circulated through the manifold, while solenoid isolation valves control the flow rate
downstream.
(a) (b)
(c)
Figure 3.3: Dynamic Drug Release Model. a) Polycarbonate manifold and the contact lens
cavity chambers. b) cross-section of the lens chamber. c) The final design of the DDRM.
DDRM can easily fit inside an incubated shaker, or any small environmental chamber.
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3.3 Materials and Methods
Corneal epithelial cells were grown on a flat cell culture insert to study the drug release
from a contact lens and its diffusion through the corneal model. The drug release from
contact lenses, as it has been discussed before, has been studied mostly in a fixed volume
of a chosen solution. In this section, the procedure for release studies of three surrogate
drugs from five commercial contact lens materials using a fixed-volume, an in vitro cell
culture as well as the dynamic release models are described.
3.3.1 Preparation of Surrogate Drug Solutions
In this study, three structurally similar ophthalmic dyes were selected to investigate the
various factors and their effects (see below) on the uptake and release mechanisms from
commercially available contact lens materials. The ophthalmic dyes fluorescein sodium salt
(FlNa), rhodamine B (RhB), and rose bengal (RsB) share a similar backbone while having
different molecular weight and partition coefficient. They all have polar surface area3
(PSA) of less than 120-140A2 which is a critical property for ophthalmic drugs that use
paracellular or transcellular routes. Table 3.1 presents the properties of these ophthalmic
dyes which will act as the surrogate drugs in this study.
The surrogate drug solutions were prepared by dissolving fluorescein sodium salt, rho-
damine B, and rose bengal (Sigma-Aldrich Chemical Co., St. Louis, MO), in Phosphate
Buffered Saline (Lonza, Walkersville, MD). Various drug concentrations were tested in a
cell toxicity study to determine the maximum permissible drug concentration, thus elimi-
nating any unwanted drug-cell cytotoxic interactions. Except for rose bengal, the surrogate
drug concentration of 10µg/mL was selected as experiments determined them to have no
cytotoxicity effect (see results section). Due to the toxicity of rose bengal, drug release
studies in the cell model were limited to fluorescein sodium and rhodamine B.
3The polar surface area of a molecule is defined as the surface sum over all polar atoms, primarily
oxygen and nitrogen, also including their attached hydrogens [https://en.wikipedia.org/wiki/Polar_
surface_area, retrieved July 2016].
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Table 3.1: Properties of the Ophthalmic Dyes Used as Surrogate Drugs
Surrogate Drug Fluorescein Sodium Rhodamine B Rose Bengal
Molecular Weight
[g/mol]
376.27 479.01 1049.85
LogP (Hydrophobicity) 2.65 1.78 8.78
Polar Surface Area† [A
2
] 89.49 52.78 89.49
Maximum Absorbance
Wavelength (nm)
490 550 548
Molecule
Chemical properties have been retrieved from Chemicalize.org®. †Cell permeability of drug
molecules with a polar surface area greater than 140A2 is less than 10% and therefore PSA of
120-140A2 is the upper limit PSA for a drug design that uses paracellular or transcellular routes.
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3.3.2 Contact Lens Materials
Soft contact lens materials are categorized into 4 groups according to their water content
and ionicity, with the addition of silicone hydrogels as the fifth group (silicone hydrogels
may also be classified in the low water content, ionic and nonionic groups). To represent the
majority of common contact lens material categories, five commercially available contact
lenses, etafilcon A, senofilcon A, hilafilcon B, polymacon, and balafilcon A, were used.
Senofilcon A and balafilcon A represent non-ionic and ionic silicone hydrogel contact lens
materials respectively. The majority of silicone hydrogel materials have low water content
(< 50%). Polymacon is a conventional non-ionic lens material with low water content
(Group I). The ionic etafilcon A and non-ionic hilafilcon B are high water content hydrogel
lens materials (Groups IV and II respectively). The properties of the five lens types used
in this study are presented in Table 3.2. Dk value, which describes the intrinsic ability
of the material to transport oxygen, are not reported as this property does not affect the
uptake and release. To ensure consistency in lens material thickness, all lenses had a back
vertex power of -3.00 diopter.
3.3.3 In Vitro Cell Culture
HPV immortalized human corneal epithelial cells 4 were cultured in keratinocyte serum
free medium (KSFM) supplemented with bovine pituitary extract, recombinant epidermal
growth factor, and Penicillin/Streptomycin (Pen/Strep) 5 (ScienCell, Carlsbad, California)
at 37◦C and 5% carbon dioxide (CO2). Fresh KM was added every other day and cells
were grown to 90% confluency in tissue culture treated flasks. Adherent cells were removed
using TryplExpress (Life Technologies, Burlington, Ontario, Canada) dissociation solution.
Cells were routinely observed for any morphological changes and were used to prepare in
vitro cornea models.
4Epithelial cells infected with an amphotropic recombinant retrovirus containing HPV-16 E6/E7 genes
to extend their lifespan.
5This supplemented medium will be referred to as KM
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Figure 3.4: Uptake and Release Models. A) Individual contact lenses were washed in PBS
overnight before soaking in 1.5mL of surrogate drug solution for 24 hours. B) Drug soaked
lenses were tested in three drug release models. The release in static models was measured
for 48 hours. a) Fixed volume release studies conducted in 1.5mL of PBS, b) In the cell
model, the lenses were immersed in 0.5mL of KM on top of a monolayer of human corneal
cells grown on a cell culture insert (PET filter). Samples were aliquoted from 1.0mL
of KM on the bottom and later were measured using UV-VIS spectrophotometry. c) In
the dynamic drug release model, an intermittent liquid flow at the rate of 1.2mL/hr is
discharged after passing over the lens encased in the chamber. The aliquots were collected
over the period of 2h in a 6-well plate.
3.3.4 Drug Uptake
Lenses were first incubated for 24 hours in 3mL of phosphate buffer saline (Lonza, Allen-
dale, New Jersey) to remove any remnants of their packing solution. Preliminary experi-
ments showed that a competitive equilibrium between the drug doping solutions (1.5ml of
the 10µg/mL) and all contact lens materials were achieved after few hours. However, the
lenses were incubated for 24 hours to ensure a consistent uptake. The incubation of lenses
in low drug concentrations as well as small volume of doping solution could be representa-
tive of the concentrations of common ophthalmic drugs (i.e, 50µg/mL for latanoprost and
40µg/mL for travoprost) as well as the limited volume of lens packaging solution (typi-
cally ranging from 1mL to 2.5mL). To determine the uptake amount by the contact lenses,
samples from the original drug doping solution and the solution after soaking the lenses
were aliquoted to measure the uptake of drug into each lens material. Fig. 3.4A illustrates
the uptake procedure.
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3.3.5 In Vitro Drug Release Models
The in vitro cornea model was prepared by growing a monolayer of human corneal epithelial
cells on a Millicell PET membrane (hanging cell culture insert) with a 1.0µm pore size. The
inserts were seeded with 105 cells/insert. The cornea models were fed fresh KM on each of
the basal and apical sides of the insert for seven days, with medium being exchanged every
other day; they were then ready for experimentation. The cell culture inserts as well as the
grown monolayer were examined by scanning electron microscopy, as shown in Fig. 3.5.
The three in vitro models used to assess drug release from the contact lenses are sum-
marized in Fig. 3.4B. In the fixed volume model, drug release into 1.5mL of PBS was
measured by taking aliquots of 100µL and replacing by fresh PBS. In the in vitro cornea
model, the contact lens was immersed in 0.5mL of cell culture media. The drug released
into the media on top of the cell monolayer and then diffused through the corneal cells and
the polyethylene terephthalate (PET) filter (also referred to as culture inserts or culture
membrane) to the bottom of the well containing 1.0mL of media. Aliquots of 100µL were
taken from the bottom of the in vitro models and replaced by fresh culture medium. For
both the fixed volume and cornea model release experiments, samples were taken at 2, 6,
24 and 48 hours. In the dynamic release experiments using DDRM, PBS was used as the
release media. The liquid was discharged from each chamber at a rate of 20µL/min, which
is higher than the physiological tear replenishment rate of 2µL/min. The flow rate was
primarily selected to ensure adequate release media was collected. The flow rate can be
adjusted for much smaller flow rates, possibly for future studies. The release experiments
were conducted for 24 hours, with the discharged liquid from the chambers being collected
over periods of 2-hour in separate wells.
3.3.6 Cell Viability Assay
After 48 release studies in the cell model, lenses and medium were removed. To obtain a
measure of the cellular viability, the MTT assay was performed. Dimethyl thiazoyl blue
tetrazolium bromide (0.5mg/mL, MTT, Sigma Aldrich, Oakville, ON, Canada) was added
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(a) (b)
Figure 3.5: a) Microstructure of Millicell PET filter, b) Tight monolayer of human corneal
cells grown on a PET filter
to the apical and basal sides of the cell culture insert and was incubated for 3 hours at
37◦C and 5% CO2. The MTT solution was then removed and isopropanol was added to
both the apical and basal sides of the insert and plates were agitated for 2 hours. The
solutions in the apical and basal sides were mixed together and samples were read in a
UV-Vis spectrophotometer at an optical density of 595 nm with a reference at 650 nm. All
results are expressed as the relative viability compared to control cells: cells incubated in
the absence of a contact lens.
3.3.7 Drug Concentration Measurements and Data Analysis
To measure the concentration of the surrogate drugs, the optical density of each sample
was read in a UV-Vis spectrophotometer at the maximum absorbance wavelength of each
of the surrogate drug compounds as listed in Table 3.1.
Results reported in this study represent the mean of at least three experiments ±
standard deviation. Experiments were performed on different days. To evaluate the signif-
icance of the differences between various contact lens materials, in vitro models and across
the time points, an analysis of variance (ANOVA) was performed, followed by multiple
pair-wise comparisons using the Holm-Sidak test and a pairwise comparison using T tests
according to the Sidak correction of Bonferroni inequality in SigmaPlot™.
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3.4 Results and Discussions
3.4.1 Surrogate Drugs’ Interaction with Cells
It has been suggested that the ophthalmic fluorescent dyes can be used as surrogate drugs to
characterize and identify desired polymeric compounds for drug delivery applications [60].
Due to their low cost and ease of measurement (i.e., UV-VIS spectrophotometry), these
compounds were used in this study to compare the uptake and release from contact lens
materials in the three studied models. The use of ophthalmic dyes as surrogate drugs also
allows direct observation of uptake, release, and the interactions of those actives with the
cells and the release model, in addition to the advantage of allowing spectrophotometric
assays for accurate measurements of uptake and release. To assess the effect of surrogate
drugs on cells, specifically the effects on cell morphology, monolayers of HCEC grown for
7 days on a collagen treated glass-bottom culture dish were incubated with 10µg/mL of
surrogate drug solutions for 2 hours, then imaged using a confocal laser scanning microscope
after rinsing the cells to remove residual dye.
The reconstructed 3-dimensional monolayer image indicated no damage to the cell layer.
The uptake of the ophthalmic surrogate drugs/dyes by cells are shown in the confocal laser
scanning electron micrographs (Fig. 3.6). After 2 hours of incubation, rhodamine B showed
no uptake by the cell cytoplasm but binding to the cell membrane, while fluorescein was
observed both on the cell membrane and in the cytoplasm. An uneven uptake of fluorescein
was noticed, whereby some cells took up more while some appeared to have almost no
fluorescein in their cytoplasm. The dark areas in both in Fig. 3.6a and Fig. 3.6b are not
indicative of holes in the monolayer, but rather indicates no fluorescence despite having
viable cells as part of the monolayer. This is consistent with previous in vitro and in vivo
results [78, 116, 117] showing inconsistent fluorescein uptake by epithelial cells. For rose
bengal, in the 3D stacked image of the cell monolayer, a severely compromised monolayer
of cells can be identified by the presence of round cells and damaged cell membranes
(Fig. 3.6f). The impact of rose bengal on corneal cell integrity was significant enough to
warrant further investigation into the cytotoxicity of the surrogate drugs in the in vitro
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cell model.
3.4.2 Cell Viability Assay of Surrogate Drugs
Cell viability studies were conducted to assess the toxicity of the surrogate drugs in vitro.
Exposing cells to cytotoxic concentration levels of these surrogate drugs would invalidate
the release results obtained from the cell studies as it would affect the barrier and metabolic
functions of the cells. To this end, solutions of the surrogate drugs were prepared in cell
culture media at 5, 10, 20, and 50µg/mL. The in vitro cell models were incubated for 24
hours with 500µL of the surrogate drugs at various concentrations added to the top only.
The in vitro monolayer was fed with 1.0mL of fresh KM on the bottom. The experiment
was repeated 5 times on different days. The viability results are presented in Fig. 3.7.
These results confirmed the confocal microscopy observations. Rose bengal even at low
concentrations significantly damaged cells (p < 0.001) as shown by a viability of less than
30% regardless of the concentration tested. Based on the viability results, drug concentra-
tion of 10µg/mL was selected for drug doping solutions since at this concentration, neither
fluorescein sodium nor rhodamine B were found to induce any cytotoxicity in the in vitro
cell model.
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Figure 3.6: Representative confocal laser scanning micrographs showing the uptake of each
surrogate drug into the cell cytoplasm or on the membrane and the effect of surrogate drugs
on cell morphology. The rainbow color spectrum represents the height of the cell layer.
a) HCEC monolayer stained with fluorescein sodium. b) 3D reconstructed image (25µm
in thickness) shows a 10µm thick cell layer. Note that the dark area in (a) and (b) do
not indicate the lack of cells, but the fact that cells did not uptake fluorescein. c)HCEC
monolayer stained with rhodamine B, only cell membrane is stained. d) 3D stacked image
shows a 10µm thick impervious cell layer. e) HCEC monolayer stained with rose bengal,
and f) 3D reconstructed image (25µm in thickness) of the monolayer shows damaged
membranes and cells with different morphology.
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Figure 3.7: The effect of surrogate drug concentration on cell viability. Viability was mea-
sured by MTT assay and is expressed as a percentage relative to cells without treatment.
Rose bengal showed a significant toxicity at all concentrations (p < 0.001) (n=5 mean ±
standard deviation).
3.4.3 Uptake Studies
The uptake results are presented in Fig. 3.8; 15µg of drug was available in the doping
solution and it can be observed that up to 14µg of rose bengal was taken up in contact
lens materials.
It was previously discussed, in Chapter 1, that both water content and polymer matrix
of a soft contact lens hydrogel can affect the uptake of hydrated species such as drugs or
ophthalmic dyes. These compounds, which have a wide range of hydrophobicity, are able to
dissolve in aqueous solutions through association/dissociation6. However, the interactions
between the polymer network and the dye depend on the surface charge and bulk properties
of the polymer, as well as the partition ratio (logP ) and the distribution ratio (logD) of
the ophthalmic dye/surrogate drug. In the case of rhodamine B and rose bengal, where
at neutral pH there is only one dominant specie, the uptake mechanism is driven by the
partition ratio and the properties of the polymer network, which explains the difference
in the uptake of these two actives within each polymer network. Thus in case of silicone
6The process whereby an ionic compound breaks into two ions, i.e, fluorescein sodium is dissociated
into sodium and fluorescein.
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Figure 3.8: Uptake data for the three surrogate drugs and five contact lens materials:
senofilcon A (SA), Polymacon (Pm), hilafilcon B (HB), balafilcon A (BA), etafilcon A
(EA). Lenses were soaked in PBS for 24 hours before an incubation in 1.5mL of doping
solution (10µg/mL). The uptake is calculated based the residual concentration in the
solution (n=6, mean ± standard deviation).
hydrogels (senofilcon A and balafilcon A) with hydrophobic regions, significantly higher
uptake of rose bengal compared to rhodamine B was observed (p < 0.001). But in case
of etafilcon A, a high water content charged hydrogel the rose bengal uptake was smaller
that rhodamine B.
Fluorescein sodium at neutral pH is dissociated into two major species with highly
hydrophilic properties. This is reflected in the distribution ratio of this compound (logD ≈
−1, negative logD values imply the tendency of a solute to remain ionized in aqueous
environment). This would explain the low uptake of fluorescein sodium compared to the
other drugs. However, in the case of balafilcon A, a silicone hydrogel with a strong surface
charge and hydrophobic bulk properties, these properties directly contribute to an increased
fluorescein uptake, while the relatively high and positive distribution ratio of rhodamine
B (logD = 2.8) consequently results in lower uptake.
The uptake results are in agreement with previously reported studies conducted by
Mahomed et al. in which uptake of several ophthalmic dyes into a wide range of contact
lens hydrogels at 10 and 100µg/mL concentrations were investigated [43].
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Figure 3.9: Cell viability after 48 hours of surrogate drug release. Viability was measured
by MTT assay and is expressed as a percentage relative to cells with no lens. The results
represent the mean of three experiments (n=3 ± standard deviation). A sterile ophthalmic
solution of benzalkonium chloride (BAK) was used as the positive control: BAK is a
preservative used in several commercially available eye drop formulations and is a well-
known irritant [89].
3.4.4 Viability Analysis
Cell viability was determined on the in vitro cell models after 48 hours of release studies.
Based on the intensity and homogeneous coloration of the monolayer with MTT, there
was no visible damage to the monolayer. MTT viability assay further confirmed visual
observation and indicated that minimal changes in cell viability and metabolism occurred
following 48-hr exposure to fluorescein and rhodamine B, as shown in Fig. 3.9. The confir-
mation of the absence of significant cell damage allow the use of the drug release results (i.e,
significant cell damage would invalidate the results of a cell model due to the disruption
in the integrity of the cell barrier function).
3.4.5 Release Results
The uptake results demonstrated the significance of the interactions between dyes and
contact lens materials. While it is logical to investigate the effect of these two in release
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experiments, it was hypothesized that the model itself would also affect the release results.
First it is important to understand the release in a small sink, since it is the most commonly
used method to study drug eluting contact lenses. In a fixed volume release, similar to the
equilibrium reached during the uptake, the concentration of the drug in the solution will
reach an equilibrium plateau.
It should be emphasized that hydrogels are highly saturated polymer networks. There-
fore, “hydrophobicity” is a relative term, which in case of certain hydrogels such as silicone
hydrogels or co-polymers may refer to hydrophobic regions in the polymer network of such
materials. If one were to compare a highly hydrophilic hydrogel to a relatively hydrophobic
hydrogel, two different mechanisms may occur:
(1) in case of a highly water-soluble compound (with distinct hydrophilic properties
such as fluorescein sodium), the uptake into a hydrophilic or charged hydrogel would be
higher than a relatively hydrophobic hydrogel (i.e, non-ionic silicone hydrogel). The release
of such a compound from the polymer network would be relatively high in both cases of
hydrophilic/ relatively hydrophobic polymer networks. However, due to the higher uptake
in hydrophilic hydrogels, both higher rate (initial burst) and higher total release (release
to uptake ratio) can be expected.
(2) in case of a highly hydrophobic compound (such as rose bengal), it can be ex-
pected to have a relatively lower uptake into a hydrophilic/ charged hydrogel, while a
significantly higher uptake into a relatively hydrophobic/ neutral hydrogel (i.e, silicone or
HEMA hydrogels). In contrast to the former mechanism, the release of a highly hydropho-
bic compound would be relatively higher in hydrophilic/ charged hydrogels when compared
to the hydrophobic/ neutral hydrogels.
These two mechanisms would be an over-simplification of the more complex behavior
that might define the interactions of a certain compound with a hydrogel. The release
for different polymer matrix and drug combinations will depend on the properties of the
polymer and interactions of the drug with the polymer and the release environment. The
release of a compound from a contact lens material in the fixed volume model creates a
baseline to compare the release from these same contact lens and drug combinations in
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the cell and the dynamic release models. Noteworthy is also the fact that the release in
a fixed volume might be very different from infinite sink models, where a significantly
larger volume of release media is refreshed after a certain period (typically every hour) to
maximize and extend the release from a contact lens, therefore hindering the concentration
of the drug to reach an equilibrium.
While the release using fixed volume and cell models were conducted for 48h, the release
results presented in this section are limited to the first 24h to allow for easier comparison
with the studies performed with DDRM. The release results for 48h are presented in
Appendix C.
In the fixed volume model as expected, regardless of the dye and lens material, a burst
release occurred. For the passive release results of fluorescein sodium in fixed volume,
depicted in Fig. 3.10a, release profiles (early burst followed by a plateau) were similar
for all lens material, but were observed at two different levels (lower release below 1000ng,
higher release above 2000ng). The two lenses with the highest amount of release, balafilcon
A and hilafilcon B, also showed the highest levels of the uptake (suggesting uptake/release
mechanism # 1, p < 0.001 compared to all other lenses). As mentioned before, fluorescein
sodium through dissociation in aqueous environment becomes very soluble. In the case of
balafilcon A and hilafilcon B, fluorescein sodium was released at significantly higher levels
compared to the other lenses (p < 0.001), either due to its high solubility in the water
phase of the hydrogel, as most likely is the case with high water content of the neutral
hilafilcon B, or through charge-charge interactions of the dissociated fluorescein species
with the hydrogel, as might be the case with the ionic silicone hydrogel balafilcon A. The
release of fluorescein sodium as a ratio of its uptake into each contact lens material using
the fixed volume release method is shown in Fig. 3.11a. Analysis of the release to uptake
ratio showed the two lenses with significantly higher uptakes (BA and HB), released more
of the drug taken up by the lens material (∼ 40%; p < 0.001), while polymacon and
etafilcon A showed the least release (∼ 20%). While senofilcon A showed the least uptake
of fluorescein sodium among all tested lenses most likely due to its hydrophobic polymer
matrix, as expected, this lens showed moderately higher release to uptake ratio, placing it
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between the groups discussed previously.
The passive release of rhodamine B from the studied contact lenses pointed towards
the role of the partition ratio between the hydrogel material and the drug, as illustrated
in Fig. 3.10b. The high uptake of a drug into a polymer network would imply a relatively
high partition ratio between the aqueous solution and the polymer matrix. As suggested
by mechanism #2, the release rate of a hydrophobic compound would decrease in such
cases. In case of polymacon, etafilcon A and to some extent hilafilcon B materials which
had the highest uptake (p < 0.001) due to the high affinity of rhodamine B toward their
polymer network, these materials also showed less release compared to balafilcon A and
senofilcon A (p < 0.001). An opposite behavior was observed for systems with low partition
ratio as was the case for balafilcon A and senofilcon A hydrogels. Rhodamine B is not
a highly hydrophobic compound (LogP = 1.78 as opposed to 7.78 in the case of rose
bengal). Therefore it should be noted that while the partition ratio was a driving factor in
uptake and release of this surrogate drug, other effects such as charge-dipole and hydrogen
bonding between the drug and polymer network might also play a secondary role. Analysis
of the release to uptake ratio results as shown Fig. 3.11b confirmed a significantly different
behavior (p < 0.001) between the lenses whereby more than 60% of the drug uptake was
released from balafilcon A and senofilcon A, while polymacon and etafilcon A showed less
than 20% of the uptake being released. Hilafilcon B, showed marginally higher release to
uptake ratio as a result of its moderately less uptake when compared to polymacon and
etafilcon A.
Due to the high hydrophobicity of rose bengal (LogPoct/wat = 8.78), the effect of the
partition ratio in release was even more dominant. Except for etafilcon A, all contact
lens materials used in this study either have a neutral polymer network (hilafilcon B and
polymacon with their HEMA polymer network), or have neutral regions (silicone hydro-
gels senofilcon A and balafilcon A). Etafilcon A has a charged polymer network of co-
polymerized HEMA-MA (methacrylic acid), which contributed to the charged properties
of this hydrogel. While neutral contact lens materials showed significantly more uptake of
rose bengal, etafilcon A showed the smallest uptake of rose bengal (p < 0.001), with an
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uptake levels even smaller than that of rhodamine B. Based on material and dye proper-
ties, it was expected that etafilcon A would release the highest amount among the tested
materials, which was confirmed by the passive release results (Fig. 3.10c). While polyma-
con is a low water content HEMA based hydrogel, HEMA lenses also have some levels of
residual methacrylic acid in their network [43]. The residual MA in the polymer network
of polymacon might shift the properties of an otherwise neutral polymer toward a charged
polymer such as etafilcon A. The rose bengal release results in a fixed volume seemed to
confirm this shift in behavior, whereby it can be seen that polymacon releases over 1000ng
of rose bengal (p < 0.001 compared to the other contact lenses), while other neutral hydro-
gels (SA, BA, and HB) barely release any. The effect of a drug with high partition ratio
in drug/lens material interactions is clearly illustrated when looking at release to uptake
ratio as shown in Fig. 3.11c. Over 24h, polymacon released 10% of the drug taken up,
while etafilcon A released above 20%. The other lens materials released less than 5% in
fixed volume model. This is in clear contrast with fluorescein sodium and rhodamine B.
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Passive release studies demonstrated that significant quantities of drug can be retained
in the contact lens after a short burst in release. The release in the dynamic environment
of the ocular surface where mechanical action of the eyelid and the constant tear replen-
ishment combined with the effects of the proteins present in tear film will certainly be
different. The objective with DDRM was to allow investigation of the effects of the tear
replenishment on drug release from contact lens. Thus the DDRM was designed to model
the tear replenishment effect on the surface of the eye, through providing a limited release
volume with constant replenishment. The flow rate used in the dynamic drug release ex-
periments was significantly higher than the tear replenishment in the eye (20µL/ml vs.
2µL/min). This most likely resulted in an increased total release of the drug from the
contact lens materials. However, this allowed, in some cases, depletion of the drugs from
the contact lens material, which otherwise would not have been possible. It should also
be noted that the release experiments in the dynamic environment were performed for 24
hours.
The release results from fluorescein sodium in DDRM are illustrated in Fig. 3.10d.
Similar to the release in the fixed volume, two distinct release levels were present, however,
while no major change in release kinetics can be observed, a minor shift towards a slower
kinetic and a plateau being reached at a later time was observed. This decline in release
rate, most apparent in case of senofilcon A was the direct effect of the dynamic release
environment. Recognizing the significantly smaller uptake of fluorescein sodium by the
contact lens materials, and the higher affinity of the dissociated surrogate drug species
toward aqueous solution, a relatively fast release was expected. However, the slowed initial
release rate would imply the limited volume in the DDRM was reducing the rate at which
fluorescein sodium can be released from the contact lens. Again, similar to the fixed volume
method, the release to uptake ratio showed release between 20− 40% of the drug uptake,
with marginally slowed initial release rate (Fig. 3.11d).
The release of rhodamine B in the dynamic environment resulted in a more contrasting
behavior. The release results as shown in Fig. 3.10e, demonstrated a significantly slower
release kinetic, and significantly higher total drug release (p < 0.001). While the release of
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rhodamine B from all lens materials was significantly higher in DDRM compared to fixed
volume model (p < 0.001), major difference was observed in the release from etafilcon
A and polymacon. In fixed volume release, the release of rhodamine B from these two
materials was curtailed due to the high affinity of rhodamine B toward their polymer
network (as suggested by the high uptake ratio). In the dynamic release model, due
to constant replenishment of the release media, the release of the drug was facilitated
(Fig. 3.12 illustrates this difference). The effects of the dynamic release model were further
amplified with the release of rose bengal. Comparing Fig. 3.11c and Fig. 3.11f, it was
evident that considerably higher quantity of the drug was released (p < 0.001) from the
contact lens materials at significantly slower rates resulting in a continuous release over
time. The release kinetics also shifted from a first-order release to a zero-order7 release.
While polymacon released most of the loaded drug, etafilcon A retained most of the drug
(Fig. 3.11f). Even when compared to the fixed volume model, etafilcon A only released
slightly more drug.
One compelling argument for using ophthalmic dyes as surrogate drugs is the ability
to visualize release through color change. Table 3.3 provides a visual assessment of drug
loaded contact lenses, before and after 24 hours release in the dynamic drug release model.
The surrogate drug/ lens material interactions ranged from high uptake (polymacon, rose
bengal), to low uptake (fluorescein sodium), significantly less release ratios (rose bengal),
and high release ratios (rhodamine B release from senofilcon A and balafilcon A). The
other benefit of using such surrogate drugs was a means to verify the uniform distribution
of flow regime inside the cavity chamber of the model. This had particular relevance to
the design of the flow system where a nonuniform color pattern on the lens would imply an
irregular flow and thus an unsuitable flow chamber design. Last but not least, the use of
ophthalmic dyes helped identify any component in the device where a significant quantity
of the drug might be absorbed.
In drug release experiments, when an ocular drug delivery device is intended to deliver
an ophthalmic compound inside the eye, and notably behind the cornea, it is important to
7In a zero-order release kinetic, the rate of the release is constant, where in a first-order release, the
rate of release was dependent on the concentration gradient of the releasing compound.
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Table 3.3: Visualization of the uptake (left) and release (right) of surrogate drugs from
various contact lens materials tested in the DDRM.
senofilcon A balafilcon A polymacon hilafilcon B
Fluorescein
Sodium
LogP = 2.65
LogD = -1
Rhodamine B
LogP=1.78
LogD = 3
Rose Bengal
LogP=8.78
LogD = 4.2
Water content
(WC)
38 38 59 36
FDA group∗
V(I)
Low WC
Non-ionic
I
Low WC
Non-ionic
II
High WC
Non-ionic
V(III)
Low WC
Ionic
Chemical properties have been retrieved from Chemicalize.org®. Each pair represents the same
contact lens after 24 hours in doping solution (uptake) and 24 hours inside the DDRM (release).
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consider the barrier effect of the cornea. To investigate the role of the cornea, simplified
in vitro cornea models were prepared by growing human corneal epithelial cells in a cell
culture insert as described in Section. 3.3.5. The concentration of the diffused drug through
a cell layer, after the release on the apical side of the cornea model are reported. This model
allowed to consider interactions with the cells to complement investigation of the surrogate
drugs and lens material interactions assessed using both passive and dynamic models.
As discussed in Section. 3.4.2, due to the cytotoxicity of rose bengal, only release studies
with fluorescein sodium and rhodamine B were performed in the cell model, furthermore
only four contact lens materials were tested as minimal differences were observed between
etafilcon A and polymacon. The release results for both dyes indicated a slower kinetic, as
well as a slower release rate (as shown in Fig. 3.10g and 3.10h). The total amount of the
drug that was released from the lens, then diffused through the cell model, was significantly
smaller than in the fixed volume method, even after 24 hours, i.e, 200ng versus 700ng for
fluorescein sodium (p < 0.001). When comparing the release of the dyes in the cell model
to the fixed volume model, the cornea model seemed to be functioning only as a barrier
against the diffusion of the these drugs. Also, in the cell model, the contact lens was
submerged in a noticeably smaller volume of the release media (500µL), resulting in a
seemingly accelerated equilibrium. The combination of the two mechanisms could explain
the shift toward slower release kinetics in the cell model. While one may conclude that the
cell model provides a very limited benefit when assessing the release from contact lenses
in case of the tested ophthalmic dyes, it must be noted that the same barrier effect exist
within the human eye whereby the rate of diffusion of the released drug will decline due
to this barrier effect.
Fig. 3.12 presents a direct comparison of the release of rhodamine B from etafilcon A
and hilafilcon B in the three models presented in this research. This figure highlights the
extended release results that may be obtained using the dynamic model, as well as the
barrier effect of the cell model when compared to the fixed volume method.
The release results of the three ophthalmic dyes at 24 hour using the three in vitro
release models are compiled and compared to provide a better perspective (Figures. 3.13,
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Figure 3.12: Comparison of the release of rhodamine B from etafilcon A and hilafilcon
B in three release models. While the release in the fixed volume (solid lines) showed an
initial burst, the release from the same contact lens materials in the cell model (dashed
lines) showed a slower release rate due the barrier effect of the cell layer. The release in the
dynamic release model(dash-dot lines) showed a significantly higher total release amount,
significantly different from cell model (p < 0.001) and fixed volume model (p < 0.001)
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3.14, and 3.15). In all three graphs, the two lighter shade of colors represents the uptake
of the surrogate drug into each contact lens material, and the remaining surrogate drug
in the doping solution. Within each contact lens material, the release after 24 hours is
presented in bar graph. This allowed an easier comparison among release models used in
these experiments. As discussed previously, the uptake of fluorescein sodium is relatively
smaller compared to the other surrogate drugs. The release of fluorescein sodium at 24 hour
time point for all contact lens materials shows the barrier effect of the cell layer resulting
in significantly less drug released (p < 0.001) (Fig. 3.13). While the release of fluorescein
sodium in the DDRM showed an increase compared to the other two models (p < 0.001),
the role of a dynamic model was more prominent in case of rhodamine B and rose bengal
as shown in Fig. 3.14 and 3.15. These results suggested that the release of rhodamine B
from balafilcon A and senofilcon A may continue until near depletion, as corroborated by
the observing the lens before and after release shown in Table. 3.3. Similar observations
can be made regarding the release of rose bengal from polymacon lens material. Fig. 3.15
also highlights the relatively high uptake-low release in case of rose bengal surrogate drug.
3.5 Conclusion
To effectively model the human eye environment and further characterize ophthalmic drug
delivery devices, it is important that experimental studies consider the limited volume and
the replenishment of the tear as well as the presence of cells. By comparing three in vitro
models (fixed volume, dynamic and cell), the results presented in this chapter aimed to
introduce a robust, reliable and cost effective testing platform to asses the drug releasing
capabilities of hydrogel contact lenses. The release results demonstrated the importance
of a dynamic release model for testing contact lens materials.
It should be noted that the use of ophthalmic dyes not only allowed the utilization of
UV-VIS spectrophotometry to accurately measure uptake and release, but also enabled a
visual qualitative estimation of the uptake and release. This unique characteristic of the
ophthalmic dyes can be exploited in facilitating rapid assessment of suitable synthesized
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Figure 3.13: Comparison of the uptake and release of fluorescein sodium in various release
models. The drug loaded into each lens material and the remaining drug in doping solution
is presented in lighter shades of color. The release in cell, fixed volume, and dynamic models
are presented for each lens material and compared to the uptake results.
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Figure 3.14: Comparison of the uptake and release of rhodamin B in various release models.
The drug loaded into each lens material and the remaining drug in doping solution is
presented in lighter shades of color. The release in cell, fixed volume, and dynamic models
are presented for each lens material and compared to the uptake results.
60
Figure 3.15: Comparison of the uptake and release of rose bengal in various release models.
The drug loaded into each lens material and the remaining drug in doping solution is
presented in lighter shades of color. The release in fixed volume and dynamic models are
presented for each lens material and compared to the uptake results. No cell experiments
were performed due to cytotoxicity of rose bengal.
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hydrogel polymers for ocular drug delivery purposes.
It is evident that modeling the microfluidic environment of the ocular surface high-
lighted interactions that would otherwise be disregarded in the fixed volume model. On
the other hand, the release results in the cell model, while they confirmed the barrier role
of the cornea, did not provide any insight into any possible interactions between the drug
eluting contact lens and the cells.
The ophthalmic dyes, unlike a large group of ophthalmic prodrugs, are not processed
in any parts of the cell metabolism pathways or the enzymes present in the cells. Prodrugs
are precursors to ophthalmic drugs that are designed to improve the drug residence time in
tear film and enhance the uptake by the cell membrane. These prodrugs through different
pathways can be metabolized into active form of the drug, inside the corneal cells, before
reaching the targeted tissue. It can be concluded that understanding the role of the corneal
cells in drug delivery studies requires investigating the release of such actives from contact
lens materials in the presence of cells.
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Chapter 4
Extended Latanoprost Release from
Commercial Contact Lenses: In
Vitro Studies Using cornea models
4.1 Introduction
Ocular drug delivery is used in the treatment of glaucoma, an intraocular disorder. Eye-
drops remains the most common drug delivery method but studies show that only about
1 to 5% of the applied dose penetrates the cornea [1]. Contact lenses have been considered
as a means to deliver topical ophthalmic drugs [4] and as discussed in Chapter 1, experi-
mental models to study drug release tend to be designed to characterize the mechanisms
of release due to polymer-drug interactions and often do not take into account cell-drug
interactions. It is well recognized that the primary drug permeation route to the front of
the eye is through the transcorneal pathways, and thus it is also important to consider the
role of corneal cells in drug release studies [25]. The lipid bilayer cell membrane retards
the permeation of hydrophilic compounds. Furthermore, the presence of cell membrane
transporters and enzymes in corneal epithelial cells actively contributes to the transport
and metabolization of prodrugs [29–32]. Using surrogate drugs loaded onto contact lenses,
the studies in Chapter 3 highlighted the barrier effect exerted by cells, however the use of
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ophthalmic dyes did not adequately represent the active interactions (transport, metabo-
lization) that occur with prodrugs. Latanoprost is used in eye-drops to treat glaucoma and
is a 432Da prostaglandin F2α analogue drug that is metabolized to its free-acid form by en-
zymes available in corneal cells [29]. Studies have also suggested that active transport using
OATP2A1 transporters contributes to latanoprost permeability across the cornea [32].
It was therefore hypothesized that the presence of corneal epithelial cells may have an
impact when assessing drug-delivery materials in vitro. In this chapter, which is published
as a standalone paper [115], we investigated for the first time, the release of latanoprost from
commercially available contact lenses using in vitro models containing corneal epithelial
cells.
4.2 Materials and Methods
4.2.1 Preparation of Drug Doping Solutions
The lens doping solution was prepared by dissolving latanoprost and latanoprost free-
acid (solution in methyl acetate, Cayman Chemical, Ann Arbor, MI) in PBS (Lonza,
Walkersville, MD). The concentration of the stock drug solution was 131µg/mL.
4.2.2 Preparation of Contact Lenses
Four commercially available contact lens materials, galyfilcon A, senofilcon A, omafilcon
A, and balafilcon A were used. The properties of the four lens types are presented in
Table 4.1. All lenses had a back vertex power of -3.00 diopter. Lenses were incubated for
24 hours in PBS (Lonza, Allendale, New Jersey) to remove any remnants of their packaging
solutions, before incubation in 1.5mL of the drug solution for 24 hours.
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4.2.3 In Vitro Cell Culture
HPV-immortalized human corneal epithelial cells, a generous gift from Dr. May Griffith
(Integrative Regenerative Medicine (IGEN) Centre, Linko¨ping University, Sweden) [79]
were cultured in keratinocyte serum free medium (KSFM) supplemented with bovine pitu-
itary extract, recombinant epidermal growth factor, and penicillin/ streptomycin (Pen/Strep)
(ScienCell, Carlsbad, California, USA) at 37◦C and 5% carbon dioxide (CO2). Fresh
medium was added every other day and cells were grown to 90% confluency in tissue cul-
ture treated flasks. Adherent cells were removed using TryplExpress (Life Technologies,
Burlington, Ontario, Canada) dissociation solution. Cells were routinely observed for any
morphological changes and were used before their eleventh passage.
4.2.4 In Vitro Drug Release Models
Three in vitro models were used to assess drug release from commercially available con-
tact lenses including diffusion through a) a Polyethylene Terephthalate (PET) membrane
(Millicell PET membrane with a 1.0µm pore size, also referred to as culture inserts, Mil-
lipore, MA, USA) with no-cells; b) a PET membrane with a monolayer of human corneal
epithelial cells (HCECs) and c) a PET membrane with a multilayer of HCECs (stratified
culture). For the two latter models, the PET membranes were seeded with 105 cells. The
corneal epithelium models were fed with KSFM on each of the basal and apical sides of
the cells layer for five days, with medium being exchanged every other day. After five
days, for the multilayer models, cell differentiation was induced by exposing the mono-
layer to an air-liquid interface. Cells were fed only on the basal side with 2% fetal bovine
serum (FBS, Invitrogen, Burlington, ON, Canada) in 1:1 Dulbecco’s minimum essential
medium (DMEM, Invitrogen) in Hams F12 nutrient medium (DMEM/F12, Invitrogen);
the medium was exchanged daily [78]. The cells grew under these conditions for seven days
and were then ready for experimentation.
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4.2.5 Measuring Drug Concentrations
Aliquots of 100µL (10 % of the total volume of the medium present in the bottom) were
taken from the bottom of the in vitro models and replaced by fresh culture medium. For
the latanaprost experiments, samples were taken at 1, 3, 6, 12, 18, 24 and 48 hours. For
latanoprost free-acid experiments, samples were collected at 1, 3, 6, and 24 hours.
Collected samples were analyzed by an enzyme immuno-assay (EIA) for latanoprost
(Cayman Chemical, Ann Arbor, MI, USA). Following the EIA kit instructions, each col-
lected sample was analyzed in duplicate and at two different dilutions. To determine the
uptake amount by the contact lenses, samples were also aliquoted from the original drug
stock solution as well as the remaining drug solutions after soaking the lenses.
The release results represent the concentration of the drug on the other side of the PET
membrane, meaning that the drug has been released from the contact lens material on top
of the membrane, then diffused through the cells, if present, and the culture membrane.
Note that the EIA kit does not distinguish between the free-acid form and ester form of
the drug.
4.2.6 Drug Concentration Calculations
As mentioned above, to measure the amount of released drug, samples were taken from
the bottom of the wells and replaced by fresh solution at each time point. Refreshing a
fraction of the medium in the bottom at each time point affects measurements. Therefore,
it is necessary to account for the dilution effect and adjust the measured concentrations to
provide an accurate measure of the concentration without the dilution effect.
Assuming the fraction of total volume of medium in the bottom which is being aliquoted
is “k”, the mass balance principle can be used to estimate for the actual concentration at
each time point.
mi = CiVb (4.1)
mi,a = CiVb + k
i−1∑
j=1
CjVb (4.2)
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In Eq.(4.1), mi refers to the amount of drug at i-th time point (ti), Ci refers to the measured
concentration at time ti, and Vb is the volume of the liquid in the bottom. An estimate of
the actual amount of drug diffused through the insert adjusted for the dilution effect, ma,i,
can be calculated using Eq.(4.2). This equation can be obtained as below by calculating
the accumulated drug amount in the medium by adding the removed amount in previous
steps to the amount of the drug available in medium at each step.
ma,1 = m1 = VbC1 ∆m1 = kC1Vb
ma,2 = m2 + ∆m1 = C2Vb + kVbC1 ∆m2 = kC2Vb
ma,3 = m3 + ∆m2 + ∆m1 = C3Vb + k(C1 + C2)Vb ∆m3 = kC3Vb
...
(4.3)
The adjusted concentration, Ca,i at i-th step can be found as below:
Ca,i = Ci + k
i−1∑
j=1
Cj (4.4)
The proposed method to estimate adjusted concentrations neglects the effect that di-
lution might have on the diffusion rate. However, for small difference between calculated
and measured concentrations, the change in diffusion rate will be insignificant.
4.2.7 Data Analysis
Results are presented as the mean of six experiments for latanoprost and three experiments
for latanoprost free-acid± standard deviation. All experiments were performed on different
days. To evaluate the significance of the differences between various contact lens materials,
in vitro cornea models and time points, an analysis of variance (ANOVA) was performed,
followed by multiple pair-wise comparisons using the Holm-Sidak test (SigmaPlot™, San
Jose, California, USA).
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4.3 Results
Preliminary studies showed that there was no decay of latanoprost and latanoprost free-
acid in the culture medium or buffered solution used in the current research (results not
presented), thus enabling the use of the enzyme immuno-assay method to measure drug
concentrations in both solutions for up to 48 hours. All the results presented have also
been adjusted according to Eq. (4.4), to take into account the small dilution that may
occur as samples are taken out and fresh medium is added.
The uptake analysis showed that 95% of the dissolved latanoprost was taken up by
the galyfilcon A and senofilcon A silicone hydrogels and 98% by the balafilcon A (thus
approximately 185µg/lens) and nearly 25% of the latanoprost solution was taken up into
omalfilcon A (50µg/lens).
4.3.1 Release in the absence of cells
In the no-cells model, release was first measured in KSFM to allow for comparisons between
all in vitro models. As shown in Fig. 4.1, an initial burst in the first 6 hours was observed,
followed by saturation, when no more drug was released, despite the available drug in the
contact lens material.
The effects of the release medium were also assessed with the three silicone hydrogel
contact lens materials for 24 hours, where the cell culture medium (KSFM) was substituted
with PBS. When compared to KSFM, the latanoprost release decreased significantly in the
no-cell model in PBS (p < 0.001), Fig. 4.2.
4.3.2 Release in the presence of a monolayer or multilayer model
Performing the contact lens release experiments in the presence of corneal epithelial cells
resulted in significant changes. As illustrated in Fig. 4.3, the amount of latanoprost re-
leased from senofilcon A was dependent on the presence of cells in the in vitro models; a
significantly higher amount of latanoprost was released in the monolayer and multilayer
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Figure 4.1: Time course of latanoprost release from four contact lens materials through
the no-cells model. Lenses were soaked for 24 hours in drug solution (131µg/mL) and then
overlayed on the model for 24 hours. Aliquots were taken at specific times from the lower
compartment and concentrations was measured using EIA. Daily dose line represents the
amount of the administered latanoprost for a glaucoma patient [27]. ∗Significantly different
from silicone hydrogel contact lens materials (p < 0.001). (n=6 Mean ± SD).
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Figure 4.2: Comparison of latanoprost release from silicone hydrogels in no-cells model.
Release from three silicone hydrogel contact lens materials in PBS as well as release from
galyfilcon A in KSFM (Keratinocyte Serum Free Medium) is shown. Lenses were soaked
for 24 hours in drug solution (131µg/mL) and then overlayed on the model for 24 hours.
Aliquots were taken at specific times from the lower compartment and concentrations were
measured using EIA. (n=3 Mean ± SD).
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models (p < 0.001) when compared to the no-cell model. Furthermore, while in the no-cell
model, no significant difference in release was observed over time, for the monolayer and
multilayer models, there was a significant increase in the amount released at 1, 3, 12, 18, 24
and 48 hrs (p < 0.05). For all contact lens materials studied, in the monolayer and multi-
layer in vitro cornea models, an extended release of drug was observed over time (Fig. 4.3).
The improved release profiles from latanoprost-soaked contact lenses was similar between
the monolayer and multilayer models (p = 0.678).
The release results for all tested commercial contact lenses are summarized in Table 4.2.
While the amount of drug released fell within potential therapeutic ranges, only 2% of the
amount of the drug sorbed into silicone hydrogel contact lens material was released after
24 hours (Table 4.2). A significantly higher amount (between 10 to 17% depending on
the model used) was released from the high water content hydrogel material, omafilcon A.
The high release of latanoprost from omafilcon A (Fig. 4.4) is in spite of the lower drug
uptake, which results in a significantly higher release percentage (p < 0.001, Table 4.2).
Latanoprost release from galyfilcon A and senofilcon A were not significantly different
(p = 0.736) and neither were they different from the release observed with balafilcon A
(p > 0.3).
4.3.3 Release of Latanoprost Free-Acid
Since in the absence of cells, the hydrolysis of latanoprost into its free-acid form cannot
happen, the release of latanoprost free-acid from contact lens materials was studied to
determine if latanoprost free-acid may be used as a substitute to latanoprost in a no-cell
model. To allow for a more complete comparison between models and drug forms, release
of latanoprost free-acid was also tested with the same in vitro models.
With latanoprost free-acid, contrary to what was observed with the ester form of the
drug, a significantly lower release occurred in the presence of cells when compared to
no-cells (Fig. 4.5). Table 4.3 presents the release of latanoprost free-acid from tested
commercial contact lenses after 24 hours for each of the in vitro models. When comparing
the amount of drug release at 24 hours in the monolayer model, the latanoprost free-acid
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Figure 4.3: Time course of latanoprost release from senofilcon A in the three in vitro mod-
els. Lenses were soaked for 24 hours in drug solution (131µg/mL) and then overlayed on
the model for 24 hours. Aliquots were taken at specific times from the lower compartment
and concentrations were measured using EIA. Daily dose line represents the amount of the
administered latanoprost for a glaucoma patient [27]. No-Cells Model: Cell culture inserts
(PET membrane) without cells, Monolayer Model: PET insert with a monolayer of human
corneal epithelial cells, Multilayer Model: PET insert with a multilayer of human corneal
epithelial cells (stratified culture). ∗Significantly different from in vitro models with cells
(p < 0.001). (n=6 Mean ± SD).
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Figure 4.4: Time course of latanoprost release from four contact lens materials through the
monolayer model. Lenses were soaked for 24 hours in drug solution (131µg/mL) and then
overlayed on the model for 24 hours. Aliquots were taken at specific times from the lower
compartment and concentrations were measured using EIA. Daily dose line represents the
amount of the administered latanoprost for a glaucoma patient [27]. Monolayer Model:
PET insert with a monolayer of human corneal epithelial cells. ∗Significantly different
from in vitro models with cells (p < 0.001). (n=6 Mean ± SD).
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Table 4.3: Latanoprost Free-Acid Release from Tested Commercial Contact Lenses after
24 Hours
Contact Lens
Material
Release Model [µg/lens]
No-Cells Monolayer Multilayer
Galyfilcon A 3.76± 1.32 3.27± 1.10 2.56± 0.46
Senofilcon A 3.06± 0.99 1.94± 0.56 2.27± 0.66
Omafilcon A 2.94± 1.73 3.14± 1.62 2.05± 1.42
Balafilcon A 5.45± 1.76$ 3.65± 0.27$ 6.26± 2.71$
n=3, Mean ± Standard Deviation. Concentration of latanoprost free-acid were measured
using EIA.
No-Cells Model: Cell culture inserts (PET membrane) without cells, Monolayer Model:
PET insert with a monolayer of human corneal epithelial cells, Multilayer Model: PET
insert with a multilayer of human corneal epithelial cells (stratified culture).
$Significantly different from other lens materials (p ≤ 0.025).
results show a significant decrease (approximately 30%) in the amounts of the drug that
has been released from galyfilcon A and senofilcon A silicone hydrogels (Table 4.2).
4.3.4 The Role of Live Cells
To study the importance of metabolically active cells, which not only provide a physical
barrier to drug permeation, but also are able to transfer and metabolize the drug, a set of
experiments was designed to compare latanoprost release from the galyfilcon A silicone hy-
drogel material through a fixed and a live monolayer cornea model. In the fixed monolayer,
cells are dead and thus metabolism of the drug cannot occur.
As shown in Fig. 4.6, in the presence of fixed (dead) cells, the amount of latanoprost
that was released from the soaked galyfilcon A lens and diffused through the monolayer
was lower in the presence of paraformaldehyde-fixed cells when compared to metabolically-
active cells. These results clearly highlight the importance of the metabolism and transport
in in vitro model of drug releasing materials.
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Figure 4.5: Time course of latanoprost free-acid release from senofilcon A in No-Cell and
Monolayer in vitro models. Lenses were soaked for 24 hours in drug solution (131µg/mL)
and then overlayed on the model for 24 hours. Aliquots were taken at specific times from
the lower compartment and concentrations were measured using EIA. No-Cells Model:
Cell culture inserts (PET membrane) without cells, Monolayer Model: PET insert with a
monolayer of human corneal epithelial cells. Daily dose line represents the amount of the
administered latanoprost for a glaucoma patient [27]. ∗Significantly different from in vitro
models with cells (p < 0.001). (n=3 Mean ± SD).
77
Figure 4.6: Time course of latanoprost release from galyfilcon A contact lens through live
and dead monolayer models. Cells were killed by fixing in paraformaldehyde. Lenses were
soaked for 24 hours in drug solution (131µg/mL) and then overlayed on the model for
24 hours. Release experiments through fixed monolayer were conducted on separate days
(n=2, Mean ± SD). The results were compared to release through monolayer models, (n=6
Mean ± SD).
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4.4 Discussion
This study was undertaken to determine the impact of the presence of cells in in vitro mod-
els of drug releasing materials. The cells used in these experiments, HPV-immortalized
corneal epithelial cells have been used previously by Griffith et. al. for corneal constructs
and have been shown to exhibit key physiological functions and biochemical marker ex-
pression of corneal epithelial cells [79].
Our initial release experiments with drug soaked contact lens material in the absence
of cells provided results similar to many others [49,51,105,107,109], showing a mechanism
of a first order release. The limited amount of drug that was released in our fixed volume
model is likely the result of the high partition ratios of the latanoprost between the contact
lens material and the aqueous solutions. Furthermore, our results from the no-cells model
suggest that latanoprost has a lower affinity toward PBS compared to KSFM. The better
solubility of latanoprost in KSFM compared to PBS is likely due to the difference in
composition, such as the presence of growth factors and other ionic compounds in the
culture medium which are absent in the buffered saline solution. While, in our experiments,
the nature of the medium was found to have a statistically significant impact on release
in the no-cell model, the actual improvement in drug release is actually insignificant when
compared to the in vitro models with cells.
Significantly higher drug release and diffusion were observed in the presence of cells.
Due to their hydrophobicity, ester prostaglandin analogues, such as the latanoprost pro-
drug, have a greater chance of diffusion through the hydrophobic corneal epithelium [111].
Furthermore, enzymatic activity will also play a role in the presence of live (metabolically
active) cells, since the hydrolysis of latanoprost prodrug is expected by cells [27,30–32] be-
fore diffusion through the cell layer. The product of hydrolysis, the latanoprost free-acid,
has a smaller partition ratio (3.06 vs 3.98) almost 10 times more soluble in aqueous solu-
tion when compared to latanoprost. Therefore, the presence of cells will improve the drug
diffusion rate. A layer of cells will also improve drug release from the contact lens material
by maintaining the concentration gradient between the lens and the solution above the
cells through metabolism of the latanoprost.
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A recent study showed that the ester form of latanoprost contributed to only 4% of
the total drug diffused through an in vitro cornea model and that no detectable amount of
ester form of the latanoprost was observed in an ex vivo model [25]. We may thus assume
that the majority of the diffused drug through the in vitro cornea models with cells is the
free-acid form.
Different latanoprost release profiles were observed among the hydrogel contact lens ma-
terials tested. Compared to the silicone hydrogel materials, the high release of latanoprost
from omafilcon A in spite of the lower drug uptake may be explained by the low affinity of
the latanoprost (an hydrophobic compound) toward the omafilcon A contact lens material,
which is a high water content hydrogel. The large partition ratio results in a low uptake by
this material when soaking in aqueous solution of hydrophobic drugs, as well as relatively
fast release rates in the release solution.
Using latanoprost esterified form, i.e. the active drug compound, latanoprost free-
acid, affected results in all models. Higher water solubility of the latanoprost free-acid
led to higher amounts of drug being released from the silicone hydrogel lens materials in
the no-cell model. As a more polar molecule, latanoprost free-acid has a lower partition
ratio between the hydrophobic silicone hydrogel contact lens materials and the aqueous
solution when compared to latanoprost. While higher amounts of latanoprost free-acid
were released in the no-cell model, lower releases were observed in the presence of cells.
With latanoprost free-acid, epithelial cells now act as a barrier against the diffusion of the
latanoprost free-acid, and hence limit the diffusion of the hydrophilic drug.
As one compares the latanoprost and latanoprost free-acid release results, it becomes
evident that similar drug release profiles cannot be obtained by replacing the prodrug with
the drug, even in the no-cell model. Not only are the amounts released significantly different
by an order of magnitude, but while all silicone hydrogel materials released similar amounts
of latanoprost, balafilcon A released significantly more latanoprost free-acid compared to
the other two silicone hydrogels. The balafilcon A/latanoprost free-acid results are likely
due to the fact that balafilcon A material has an overall net negative charge due to the
incorporation of some acidic material components [27] and its surface charge increases the
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hydrodynamic attributes of the material [118], therefore increasing the role of adsorption
of the hydrophilic drug on the surface of the contact lens during the uptake process and
its subsequent release in solution. Nevertheless, taken together, our latanoprost free-acid
results highlight the relevance of using in vitro models with cells when studying release of
a prodrug that will undergo hydrolysis before diffusion through the tissue to the site of
treatment.
Due to the lack of previous in vitro studies on prostaglandin analogues, our results can
only be compared to the release of drugs from the contact lens materials with similar size
and hydrophobicity. Previous in vivo studies have shown a prolonged release of relatively
hydrophobic drugs such as ketotifen [108] and lomefloxacin [110], however such release
profiles could not be replicated in vitro using a fixed volume release model [51, 109]. The
extended release of latanoprost observed in the monolayer and multilayer in vitro models
correlates well with the extended release profiles of the hydrophobic drugs observed in
vivo [108, 110]. The release results of latanoprost in the no-cells model is also comparable
to the release results of hydrophobic compounds in fixed volume solution [51, 109]. The
significant role of cell metabolism and transport was further demonstrated using fixed
(metabolically inactive) cells. Taken together, our results suggest that the absence of cells
in in vitro models of drug release likely contributes to the contradiction between these in
vitro and in vivo studies [51, 108–110].
4.5 Conclusion
Poor release results from commercially available contact lens materials soaked in hydropho-
bic compounds such as latanoprost have been obtained with fixed volume release models
similar to the no-cells model used here. However, we have demonstrated, using drug-soaked
silicone hydrogel materials, that the amount of drug diffusing through an in vitro cornea
model is in the order of 2−3µg over a period of 24 hours, which is comparable to the 1.5µg
of drug in every drop of the commercial latanoprost. Our results emphasize the impor-
tance of the presence of cells when characterizing the release of drug-delivery materials and
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demonstrate how experimental in vitro models have a significant impact on the outcomes
of testing ophthalmic drug delivery materials. Our in vitro study suggests that silicone
hydrogels have the potential to deliver latanoprost effectively over an extended period of
time. Fig. 4.7 presents a graphical abstract of the key results and the drug uptake and
release model used in this study.
Figure 4.7: Impact of corneal epithelial cells on latanoprost drug release from a contact lens
material. Commercial contact lenses were washed in PBS overnight, before the soaking in
drug solution for 24hrs. The drug release from contact lenses were measured for 24 to 48
hours in various release models.
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Chapter 5
Tear Replenishment System:
A More Realistic Approach to Ocular Surface Biocompatibility
Studies
5.1 Overview
While there is a constant exchange of fluid over the ocular surface, conventional in vitro
cell models poorly mimic this physiological condition/environment. Most in vitro models
currently do not remove/replenish nutrients at the air-liquid interface during incubation,
and thus the cells or ophthalmic materials are exposed to the same concentration over
time. While a monolayer of corneal epithelial cells is capable of forming tight-junctions, in
a stratified cornea model, differentiation of epithelial cells and formation of a superficial
epithelial cell layer that forms tight-junctions is achieved through the creation of an air-
liquid interface. The tight-junctions are an essential characteristic of the cornea’s barrier
function [82].
In order to reproduce tear replenishment in vitro, a method and a device are needed
to deliver artificial/non-artificial tear liquid to an in vitro ocular cell culture model and
the ophthalmic material interacting with the ocular cell model, while maintaining the air-
liquid interface. In this chapter, this device and method hereinafter referred to as “Tear
Replenishment System (TRS)” will be put forth as a solution.
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To assess the value of the TRS in studying ophthalmic drug delivery devices, the re-
lease of latanoprost from three commercial contact lenses under replenished conditions was
investigated. The results, presented in this chapter, were compared to the release from the
same contact lenses using the conventional immersion model. To this end, curved cornea
models (CCM) were prepared and are fully described in the following section. It should
be noted that the viability studies using TRS covered in this chapter are published [119].
5.2 In Vitro Curved Cornea Models
Cornea models have shown good in vitro/in vivo correlation in drug permeation studies
when compared to ex vivo models [25]. This makes them a more standardizable and cost
effective substitute for animal studies. Monolayers and multilayers of immortalized human
corneal epithelial cell grown on cell culture inserts are used as in vitro cornea models
for a variety of cytotoxicity and biocompatibility tests [87, 89]. None of the commercially
available models such as HCE by SkinEthic, EpiOcular by MatTek, and Clonetics by Lonza
are suitable for contact lens studies due to their limited surface area (the well size of these
models is between 6 and 8 mm compared to the 13-16 mm diameter of a contact lens).
To overcome the limitations of these models, a curved cornea model was developed at
the Materials Interactions with Biological Systems (MIBS) lab to study the interactions of
contact lens materials and multipurpose solutions [78]. The curved cornea models used in
this research project followed those protocols with some modifications as described in this
section.
5.2.1 In Vitro Cell Culture
HPV-immortalized human corneal epithelial cells were cultured in keratinocyte serum
free medium (KSFM) supplemented with bovine pituitary extract, recombinant epidermal
growth factor, and Penicillin/Streptomycin (Pen/Strep) (ScienCell, Carlsbad, California)
at 37◦C and 5% carbon dioxide (CO2). Fresh medium was added every other day and cells
were grown to 90% confluency in tissue culture treated flasks. Adherent cells were removed
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using TryplExpress (Life Technologies, Burlington, Ontario, Canada) dissociation solution.
Cells were routinely observed for any morphological changes and were used before their
eleventh passage.
5.2.2 Preparing Curved Cornea Models
The curved cornea models (CCMs) (monolayer and stratified) were grown on a Millicell-HA
(mixed cellulose esters) membrane (Millipore, Billerica, MA, USA) with a 0.45µm pore size.
The 30 mm diameter filters were first formed using a custom-shaped curved forming mold
(Fig. 5.2a) as shown in Fig. 5.1. Silicone rings were punched into rings (inner diameter
of 15.9 mm and an outer diameter of 23 mm) from Press-to-Seal sheets with adhesive
(Life Technologies, Burlington, Ontario, Canada) using an in-house fabricated punch die
(Fig. 5.2b). Once cut, the rings were disinfected with 70% ethanol and placed on top of the
curved filters. The assembled inserts were then UV sterilized. After sterilization, inserts
were coated with collagen type I (0.05mg/ml - 30min at 37◦C). The inserts were then
rinsed with PBS before adding cells.
The curved inserts were seeded with 6 × 105 cells/insert. The CCMs were fed with
KSFM on each of the basal and apical sides of the curve for the first seven days, with
medium being exchanged every other day. The monolayer CCMs were ready for experi-
mentation at this point. In case of stratified CCMs, after day five of KSFM feeding, cell
differentiation was induced by exposing the monolayer to an air-liquid interface. Cells were
fed only on the basal side with 2% Fetal Bovine Serum (FBS) in 1:1 Dulbecco’s Minimum
Essential Medium (DMEM) in Ham’s F12 nutrient medium (DMEM/F12) and medium
was exchanged daily. The cells grew under these conditions for seven days and were then
ready for experimentation. The scanning electron microscopy as well as the cross-section
of the stratified corneal epithelium are presented in Fig. 5.3. The fixed CCMs (in 10%
neutral buffered formalin) were sectioned and stained with hematoxylin and eosin (H&E).
The H&E staining results demonstrated the integrity of the stratified corneal cells firmly
attached to the cellulose filter. Also, as shown in SEM micrographs of the mixed cellulose
ester filters, Fig. 5.4, the microstructure of the filters, which plays an essential role in cell
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(a) (b) (c)
Figure 5.1: Mixed Cellulose Ester Filters: a) before and b) after deforming the filters c)
and with a silicon ring
(a)
(b)
Figure 5.2: a) The forming mold to custom-shape the cellulose ester filters and, b) The
punch die to cut silicone Press-to-Seal sheets that limit the cell growth to the curved area
of the filters in curved cornea models
adhesion to the surface, was retained after the curve-forming process.
5.3 A Microfluidic Approach to Tear Replenishment
Mimicking tear replenishment in the eye required the delivery of a tear analogue to the
surface of the in vitro cornea model at a rate within the range of a physiological tear flow
rate, in a recurring fashion. The objective was to cover the surface of the cornea model
with a small amount of artificial tear liquid sufficient to hydrate the surface of the model
and maintain the air-liquid interface. Designing a fully operational microfluidic device
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(a)
(b)
Figure 5.3: a) Scanning electron microscopy analysis, and b) H&E staining of a multilayer
curved cornea model. In (a) loosely attached cells on top of a compact stratified corneal
epithelial cells can be observed. Due to the lack of blinking, cornea models grown in vitro
lack the ability to properly discard naturally occurring cell shedding. H&E staining shows
the integrity of the multilayer corneal cells firmly attached to the cellulose filter.
(a) (b)
Figure 5.4: a) Microstructure of cellulose ester filter a) before, and b) after forming, using
the forming mold. The filter maintains its porous micro-structure which is essential for cell
adherence and cell growth promotion.
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required multiple iterations around the dimensional parameters as well as the type of fluid
flow of the system. The final design is a reliable platform that allows control of experiment
parameters through an interactive interface.
5.3.1 Generating an Intermittent Micro Flow
To bring artificial tear liquid to the surface of the in vitro cornea model, injection of a
liquid through a needle or a nozzle could be considered. A spectrum of flows, from a
slow drip, to a laminar jet, to a spray, can be achieved based on the flow parameters of
the jet. The laminar flow does not adequately mimic the intermittent nature of the tear
replenishment on the surface of the in vitro cornea model. Therefore, it is necessary to use
either a dripping flow or an atomized/aerosolized flow to model the tear replenishment.
In a dripping flow, a droplet forms when the force of gravity on the liquid exceeds
the surface tension, therefore the liquid is pulled away from its attachment. To achieve
a physiological tear flow rate of approximately 100µL/hr [45], it can be shown that the
internal diameter of the needle needs to be smaller than 10µm. Due to the complexities
of using such a needle, mostly because of clogging by floating particles in artificial tear
liquid, such a needle is not suitable for the tear replenishment system. Considering that
the nature of the flow is intermittent, larger diameters for shorter intervals can be used.
Spraying a specific amount of liquid with the frequency of human blinking can also
be utilized to cover the surface of the in vitro cornea model in order to recreate the tear
replenishing effect. “Spraying occurs when the cohesive and disruptive forces applied to the
surface of a cylindrical jet of liquid generates small perturbations that can amplify under
favorable conditions to disintegrate the jet into small droplets” [120]. In the following
section the design based on these types of flow will be discussed.
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5.3.2 Design Constraints and Criteria
Any microfluidic device that models tear replenishment of the human eye in vitro is required
to:
1. deliver a reproducible and adequately small volume of tear solution analogue inter-
mittently to the surface of the cornea models,
2. deliver sterile tear solution under aseptic conditions through biocompatible micro-
fluidic components with minimal interaction between liquid and the system to mini-
mize the risk of contamination or leaching of any components that may interact with
cells,
3. achieve sterility for the device components through readily accessible means,
4. integrate within a cell culture incubator,
5. accommodate the readily available cell culture plates and inserts.
Two types of fluid flow were used in the design of the TRS. In the initial design,
properties of an atomized jet were exploited to hydrate the surface of the CCMs. The
initial design proved that the microfluidic approach could be employed successfully to
model the tear replenishment in vitro. However, the impediment to using the spray jet
was the damage caused by the fast fluid jet to the integrity of the in vitro cornea model.
Subsequent to the first complete design/implementation of the TRS, significant improve-
ments in every aspect of the system were made in the second design. The second iteration
of the TRS took advantage of a dripping flow to deliver a tear solution analogue, while
allowing individual collection of supernatant liquid (excess “tear” collected on the CCMs),
and closer monitoring of the performance of the system using a more robust and flexible
circuitry. As a first step, computer-aided numerical simulations were used to validate the
microfluidic system’s design. Also a closed system approach to the microfluidic system
allowed for maintaining the sterility of the system. Corrosion in the initial design, due
the acidic environment of the incubator, was addressed by encasing most components in
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Table 5.1: Tear Solution Properties
Symbol Parameter value
ρ tear liquid density 1 g/cm3
µ tear liquid viscosity 4.4-8.3 mPa.s [121]
σ surface tension against the air 0.043 N/m [122]
a sealed stainless steel enclosure, and relocating electronic circuits to outside of the incu-
bator. The most significant improvement in the final design was adopting modular design
concepts. This enabled optimization of the individual subsystems thus minimizing the
required troubleshooting effort as well as the rate of failure. Further details of the designs
are provided in the following sections.
5.3.3 Atomized Liquid Jet Design (TRS v1.0)
The classification of modes of disintegration of a jet as well as the idealized and actual
breakup of a low velocity jet is illustrated in Fig. 5.5. At small flow rates, the liquid jet
will breakup after traveling the distance L, referred to as the “Rayleigh varicose breakup
length”, according to the empirical equation shown below:
L = 19.5d0(1 + 3Oh)
0.85
√
We (5.1)
in which Oh, Ohnesorge number is defined as:
Oh =
µ√
ρσd0
=
√
We
Re
(5.2)
where We and Re are the Weber and Reynolds numbers.
Table 5.1 presents some of the properties of the tear solution, although properties of
an artificial tear solution [64] will be slightly different from human tears.
For the physiological tear flow rates and fluid properties shown in Table 5.1, using
Eq.(5.1), the Rayleigh varicose break-up length will be as short as a few micrometers for a
nozzle exit diameter of 50µm, which implies that the liquid jet will atomize upon exiting
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cornea 
model, we need to study injection of artificial tear liquid, 
thorough a needle or a nozzle. Depending on the rheological 
parameters of the jet, we may have from dripping to a laminar
jet and from there to a fully developed spray region. Based on 
the requirement of the system which needs to model the tear 
replenishment system, we may design a hydraulic system that
A droplet forms when the gravity force on the liquid 
exceeds the attaching surface tension force, therefore the
liquid is pulled away from its attachment. The mass of the
droplet is determined by equating the gravitational and surface 
tension forces on the droplet. For the slow emission on liquid 
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Fig. 1. Classification of modes of disintegration of a jet. (a) Idealized and, 
$ %
Figure 5.5: Classification of modes of disintegration of a jet. A) Ideal and, B) Actual
breakup of a low velocity jet. Diagram is adapted from [120]
the nozzle.
Based on these calculations, the microfluidic system shown in Fig. 5.6 is proposed for
use as a tear replenishment system. The proposed system uses a pressurized supply line
from which a tear solution analogue is sprayed through a nozzle onto the surface of the
in vitro cornea model. The amount of sprayed solution is controlled through a series of
solenoid isolation valves by adjusting the fraction of time that each valve is open. The
air-liquid interface is maintained by collecting the sprayed solution and draining it from
each well.
To assess the feasibility of the microfluidic system’s design, LMS Imagine.Lab AMESim©
was used for modeling the proposed system. The numerical modeling results showed an ad-
justable flow rate within the desired range could be achieved for the duty cycle of 25−100ms
in the isolation valves. The total accumulative volume transferred to each well over a period
of one min was calculated to be 2.2µL as depicted in Fig. 5.7.
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Figure 5.6: Schematic of the “atomized jet based” tear replenishment system: the solenoid
pump provides enough back pressure to a series of isolation valves to control the flow
rate as well as the duty cycle of the tear analogue spray over the curved cornea model.
The vacuum pump drains the supernatant liquid from the top the CCMs into the waste
container.
Figure 5.7: The accumulative transferred volume in each well over one minute period using
a 250ms opening time of the isolation valve.
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5.3.3.1 Mechanical Design
The situation that must be resolved via this design is one of a microfluidics device which
can spray tear analogue on the surface of an in vitro curved cornea model. The tear in
the human eye is produced in the rate of 0.5-2.2 µL/min, which is spread over the eye
through blinking nearly 10 times every minute [93, 94]. Therefore the designed system
requires providing an adjustable amount of tear fluid within the range of 1 − 4µL/min,
10 times in a minute. A solenoid operated micro-pump from Bio-Chem Fluidics™ was
used to pump the tear analogue through PTFE tubing (Bio-Chem Fluidics, NJ, USA). All
the components used in the device are sterilizable and biologically inert. The sterile tear
analogue solution passes through solenoid operated isolation valves (Bio-Chem Fluidics,
NJ, USA) and ceramic nozzles (CoorsTek®, USA) before being sprayed on the surface
of the cornea model and then drained through another solenoid operated micro-pump.
Fig. 5.8 shows the designed device. The implemented tear replenishment system and the
interior of the device are presented in Fig. 5.9.
5.3.4 Dripping Flow Design (TRS v2.0)
While the goal in the “atomized jet design” was to deliver an adjustable rate of 1−4µL/min
to the surface of CCMs, as it will be discussed in the following sections, it significantly
damaged the integrity of the cornea model. Changing the flow regime into dripping was
favored over other flow types as it would generate an intermittent flow. The atomization
in the initial design occurred due to the significantly higher fluid velocity while exiting the
nozzle. To generate a dripping flow, a needle could be used instead. However, to maintain
similar flow rate to the initial design, the needle diameter requires to be less than 10µm.
Such needle does not exist nor can it be reliably utilized for delivery of the tear analogue
that may contain small particles. To overcome this limitation, a needle with an internal
diameter of 50µm was adopted. The droplet size is governed by the balance between the
gravity on the liquid and the surface tension force. The larger diameter needle impacts the
droplet size. To retain the frequency at which the tear solution is delivered to the surface
of the CCMs, the total flow rate of the TRS increases to 1mL/hr which is 10 times larger
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Solenoid Valve
Polyacrylic Manifold
Aligning Rings
Cell Culture Inserts
6-well Plate
Polyacrylic Enclosure
Stainless-Steel Screw
Flow channels
Nozzle Assembly
Luer-lock Adapter
Luer-lock Needle
Curved Cornea Model
(a)
(b)
Figure 5.8: a) Exploded view of the TRS v1.0 and its various components. b) Schematic
cross section of the TRS with the nozzle assembly and the curved cornea model.
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(a) (b)
(c) (d)
Figure 5.9: The Tear Replenishment System v1.0. a) and b) Polyacrylic manifold, nozzles
and culture plate can be identified. A cell culture plate with in vitro cornea models, the
cornea models appear dark purple as they have been stained with a metabolic dye following
experiments in the TRS; c) Closed TRS: the system is built to ensure that testing with the
in vitro cornea model is performed under aseptic conditions. d) The TRS is designed to
fit in a cell culture incubator so that cells are exposed to the proper growing environment.
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Figure 5.10: Schematic of the “dripping flow based” tear replenishment system, v2.0. A
solenoid pump provides enough back pressure to a series of isolation valves to control the
flow rate as well as the duty cycle of the tear spray over the curved cornea model. An air
pump creates a relative vacuum which drains the supernatant liquid from the top of each
CCM and collects them individually.
than physiological tear replenishment rate. While significantly larger, the flow rate is still
sufficiently small to mimic the effect of tear replenishment in vitro.
The final design of the microfluidic system, as shown in Fig. 5.10, improves upon the
initial design. The proposed system uses a pressurized supply line; however, the tear
analogue is transferred through a needle above the surface of the in vitro cornea model
before dripping onto the surface. The amount of delivered solution is controlled through
a series of solenoid isolation valves similar to the former design. The air-liquid interface is
again retained by collecting the supernatant solution and draining it from each well into
containers corresponding to each individual CCM.
5.3.4.1 Mechanical & Electrical Design
An air jacketed CO2 mini incubator (VWR International, Mississauga, Canada) was adapted
to enclose the tear replenishment system and provide ideal cell culture environment (100%
humidity, 37◦C temperature , and 5% CO2). The mechanical components of the TRS is
divided into “tear replenishment module” and “supernatant drainage module”. While the
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tear replenishment module requires to be accessible to place/remove the cell culture plate
containing the CCMs, the supernatant module, along with the rest of electro-mechanical
components are encased in a stainless-steel enclosure. The same solenoid operated micro-
pump from Bio-Chem Fluidics™ is used to pump the tear analogue through PTFE tubing
(Bio-Chem Fluidics, NJ, USA). All the electrical components are located in the electrical
panel of the incubator. The electro-mechanical components are passed through the incuba-
tor compartment using a water-proof, chemically resistant connector. All the components
used in the device are sterilizable and biologically inert. The sterile tear analogue solu-
tion passes through solenoid operated isolation valves (Bio-Chem Fluidics, NJ, USA) and
stainless-steel needles (Hamilton Company®, Nevada, USA) before dripping on the sur-
face of the CCM and then drain through another solenoid operated pinchvalve into a 6-well
plate encased in the vacuum chamber as part of the supernatant drainage module. Relo-
cating electrical components also eliminates an extra heat source that would destabilize the
incubation temperature. Fig. 5.11 shows the designed system and the two modules. The
implemented tear replenishment system as well as the interior of the device are presented
in Fig. 5.12.
The electro-mechanical components of the system are driven and controlled using a
small board computer (SBC) running Linux which provides a user-interface through the
touchscreen enabled lcd on the front of the incubator panel.
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Tear Replenishment Subassembly
Electrical Connnectors
Tear Analogue Container
Vacuum Chamber
(a)
(b)
Figure 5.11: a) Exploded view of the TRS v2.0 and its various components. b) Schematic
cross section of the TRS v2.0 with the nozzle assembly and the stratified curved cornea
model.
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(a) (b)
(c) (d)
Figure 5.12: Tear Replenishment System v2.0, “Dripping Flow Based” Design. A 6-well
plate with 6 CCMs is placed inside the replenishment subassembly a) before, b) after
clamping the subassembly to seal the 6-well plate; c) Tear analogue dripping from micro-
needle d) The TRS is designed to fit in a cell culture incubator so that cells are exposed
to the proper growing environment.
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5.4 Materials and Methods
5.4.1 Preparation of The Tear Replenishment System
The microfluidics system was sterilized by running 70% Ethanol through the device and
then PBS. The device awas then required to stabilize near 37◦C to eliminate temperature
fluctuations as well as condensation on the device components during the experiment.
Afterwards, six curved cornea models were placed in the device under aseptic conditions,
then the entire device was transferred back to the cell culture incubator and experiments
were performed for 12 hours.
5.4.2 Viability Studies: Preparation of Contact Lenses
Two commercially available contact lens materials, balafilcon A, and etafilcon A were se-
lected for this study and their properties are listed in Table 5.2. Lenses had back vertex
power of -3.00. Phosphate buffered saline, recognized to be biocompatible [88], was used as
the negative control lens solution. A sterile ophthalmic solution of benzalkonium chloride
(BAK) was used as the positive control: BAK is a preservative used in several commer-
cially available eye-drop formulations and is a well-known irritant [89]. The commercially
available Moisture Eyes (ME; Bausch & Lomb, Rochester, NY, USA) has a BAK concen-
tration of 0.01% w/v. Contact lenses were removed from their packaging and soaked for 24
hours either in Phosphate Buffered Saline (PBS, Lonza, Allendale, New Jersey) or in the
undiluted BAK-containing solution. Each lens was totally immersed in the solutions in a
sterile 12-well polystyrene plate and all procedures were performed under sterile conditions.
5.4.3 Viability Studies: Experiments Using TRS v1.0
To ensure that the in vitro TRS system was a viable platform to model the ocular surface,
the ability of the in vitro tear replenishment device to hydrate the topical surface of a
cornea epithelial model with and without contact lenses was tested and compared to the
conventional immersion method.
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The contact lenses used in this study were soaked either in PBS or in a benzalkonium
chloride containing solution, Moisture Eyes. For lens placement, cells were fed with fresh
KSFM on the basal side of the cell culture inserts. Apically, 500µL of KSFM was added to
wet the surface. Solution-soaked and PBS-soaked contact lenses were then removed from
their respective incubation solution and were placed concave-side down on top of the curve.
300µL of KSFM was then applied to the top of the wells that were not subjected to spray
(no-replenish condition) to a total of 800µL of KSFM. The rest of the wells were subject to
spray (replenished condition). The contact lenses, onlayed on the curved cornea models,
covered the entire surface of the stratified CCMs.
In the experimental design, there were two different lenses and two different solutions
tested for 2 and 6 hours. Each of the 8 combinations were tested, and all combinations
including controls were subjected to both replenish and no-replenish conditions.
5.4.4 Cell Viability Assay
After 2, 6 and 12 hours incubation (2 and 6 hours for viability studies and 12 hours for
drug release studies, respectively), lenses and medium were removed. To obtain a measure
of the cellular viability, the MTT assay was performed. Dimethyl thiazoyl blue tetrazolium
bromide (0.5mg/mL, MTT, Sigma Aldrich, Oakville, ON, Canada) was added to the apical
and basal sides of the cell culture insert and was incubated for 3 hours at 37◦C and 5% CO2.
The MTT solution was then removed and isopropanol was added to both the apical and
basal sides of the insert and plates were agitated for 2 hours. The solutions in the apical
and basal sides were mixed together and samples were read in a UV-Vis spectrophotometer
at an optical density of 595 nm with a reference at 650 nm. All results are expressed as
the relative viability compared to control cells: cells incubated in the absence of a contact
lens and without replenishment (immersion model).
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5.4.5 Drug Release Studies: Drug Doping Solution
The lens doping solution was prepared by dissolving latanoprost (solution in methyl acetate,
Cayman Chemical, Ann Arbor, MI) in PBS (Lonza, Walkersville, MD). The concentration
of the stock drug solution was measured at 123µg/mL.
5.4.6 Drug Release Studies: Preparation of Contact Lenses
Based results previously obtained [115], three commercially available contact lens materials,
senofilcon A, etafilcon A, and balafilcon A were selected. The properties of the three lens
types are presented in Table 5.2. All lenses had a back vertex power of -3.00 diopter.
Lenses were incubated for 24 hours in PBS (Lonza, Allendale, New Jersey) to remove any
remnants of their packaging solutions, before incubation in 1.0mL of the drug solution for
24 hours.
5.4.7 Drug Release Studies: In Vitro Drug Release Models
The in vitro curved cornea models were used to assess drug release from commercially
available contact lenses. The curved cornea models were grown on a Millicell-HA (mixed
cellulose esters) membrane (Millipore, Billerica, MA, USA) with a 0.45µm pore size. The
curved inserts were seeded with 6 × 105 cells/insert. The CCMs were fed with KSFM
on each of the basal and apical sides of the curve for seven days, with medium being
exchanged every other day. A confluent monolayer with formed tight junctions grew under
these conditions and was then ready for experimentation at day 7.
5.4.8 Drug Release Studies: Measuring Drug Concentrations
Aliquots of 200µL (10 % of the total volume of the medium present in the bottom) were
taken from the bottom of the in vitro models and replaced by fresh culture medium for
both replenish and no-replenish models. The samples were taken at 1, 4, 8, and 12 hours,
as well as an aliquot of the supernatant solution.
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Table 5.2: Properties of the Contact Lens Hydrogel Materials Used in the Tear Replenish-
ment System
Commercial name Acuvue 2 Acuvue Oasys† PureVision 2‡
(US adopted name) etafilcon A senofilcon A balafilcon A
Manufacturer
Johnson &
Johnson
Johnson &
Johnson
Bausch &
Lomb
Water content (WC) 58 38 36
Principal
Monomer
HEMA + MA
mPDMS +
DMA + HEMA +
siloxane macromer +
TEGDMA + PVP
NVP + TPVC +
NVA + PBVC
FDA group∗
IV
High WC
Ionic
V(I)
Low WC
Non-ionic
V(III)
Low WC
Ionic
∗ FDA (Food and Drug Administration) categorizes all silicone hydrogel contact lenses as group
V, however it is more practical to use groups for conventional hydrogels to better understand
their material properties. † Internal wetting agent (PVP) has been used to compensate for the
low wettability of silicone hydrogels. ‡ Plasma oxidation process has been used as the surface
treatment to increase wettability.
HEMA, HydroxyEthyl MethaAcrylate; MA, Methacrylic Acid; mPDMS, monofunctional Poly-
DiMethylSiloxane; DMA, DiMethAcrylate; TEGDMA, Tetra-EthyleneGlycol DiMethAcrylate;
PVP, Polyvinylpyrrolidone; NVP, N-Vinylpyrrolidone; TPVC, Tris(trimethylsiloxysilyl) Propy-
vinyl Carbamate; NVA, N-Vinyl Aminobutyric Acid; PBVC, Poly(dimethysiloxy)di (silylbutanol)
Bis(Vinyl Carbamate)
Collected samples were analyzed by an enzyme immuno-assay (EIA) for latanoprost
(Cayman Chemical, Ann Arbor, MI, USA). Following the EIA kit instructions, each col-
lected sample was analyzed at four different dilutions. To determine the uptake amount
by the contact lenses, samples were also aliquoted from the original drug stock solution as
well as the remaining drug solutions after soaking the lenses.
The release results represent the concentration of the drug on the basal side of the
CCMs, meaning that the drug has been released from the contact lens material on top of
the membrane, then diffused through the cells and the cell culture insert’s membrane. It
should be noted that the EIA kit does not distinguish between the free-acid form and ester
form of the drug.
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5.4.9 Data Analysis
For all studies, a minimum of three experiments were performed on different dates. All
viability results are expressed as relative viability compared to control cells, cells grown
in the absence of a contact lens under no-replenish condition. Results are reported as the
mean of at least three experiments ± standard deviation. To evaluate the significance of
the differences in cell viability, an analysis of variance (ANOVA) was performed, followed
by multiple pair-wise comparisons using the Holm-Sidak test and a pairwise comparison
using T tests according to Sidak correction of Bonferroni inequality in SigmaPlot™.
5.5 Results & Discussions
5.5.1 TRS 1.0 - Viability Studies
Initial experiments using the tear replenishment system v1.0 showed damaged to the in
vitro cornea model due to the strong focused jet, which appeared to be washing cells from
the membrane, as shown in Fig. 5.13. However, after increasing the nozzle diameter to
150µm, exposing the stratified CCMs to the tear replenishment system did not result in
any visible cell damage when compared to the immersion model (see Fig. 5.14).
This was further confirmed by the cell viability results; following exposure to replenish-
ment conditions for up to 6 hours, in the absence of a lens, cell viability of the CCM
was not affected as shown by a viability of 96 ± 11% compared to control (no lens, no-
replenishment) (p > 0.5). Furthermore, no difference in viability was observed with the
multilayer exposed to PBS-soaked lenses with or without replenishment (Fig. 5.15).
As a means to identify a positive control and to gain a better understanding of the
potential effect of replenishment, BAK-soaked lenses were tested and used with the TRS
to determine if the release of a cytotoxic compound from a contact lens on the stratified
cornea model would be affected by the replenishment conditions. While no significant
differences were observed at 2 h (Table 5.3), following a 6 h exposure, a significant reduction
in viability was observed with BAK-soaked etafilcon A under both replenishment and static
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(a) (b)
Figure 5.13: Initial results from Tear Replenishment System v1.0 with damaged cornea
models a) tear replenishment in the presence of a contact lens, b) tear replenishment in
the absence of contact lens.
Figure 5.14: Visual confirmation of cell viability for “atomized jet based” TRS after mod-
ification to flow regime. CCMs stained with metabolic dye (MTT) following 2 hour incu-
bation in the presence of tear replenishment (well 1) and in the absence of replenishment
(well 2, well entirely immersed in solution). No damage to the multilayer can be observed
following exposure to solution being sprayed on the surface intermittently.
immersion conditions (no replenishment, Fig. 5.15). Furthermore, tear replenishment had
a significant effect on viability whereby exposure to BAK-soaked etafilcon A in a dynamic
fluid-exchange system resulted in a significantly lower viability when compared to static/no
replenishment conditions (p = 0.03). With BAK-soaked balafilcon A, a reduction in cell
viability, albeit not statistically significant when compared to the no-lens and PBS-soaked
balafilcon A control (p > 0.1) was observed and the tear replenishment had no effect
(p > 0.75).
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Figure 5.15: Effect of tear replenishment vs. immersion conditions (no replenishment) on
corneal epithelial cell viability after 6 h incubation in TRS device. Viability was measured
by MTT assay and is expressed as a percentage relative to in vitro cornea model without
contact lens and spray. (n=3-4 ± standard deviation). ∗Significantly different from no lens
and PBS-soaked lens control, (p < 0.01); #Significantly different from no replenishment
sample, (p = 0.03). PBS, phosphate buffered-solution; BAK, benzalkonium chloride
5.5.2 TRS 1.0 - Viability Studies: Discussion
Results from both the no-lens control samples and the PBS-soaked lenses demonstrated
that exposure to the tear flow from the TRS did not damage the stratified CCM and thus
the TRS can be safely used to assess lens-cell interactions in a dynamic system. While BAK
toxicity has been reported before, in vitro models have mostly been used to investigate the
cytotoxicity of BAK solution alone [123,124]. To our knowledge, this is the first time that
HCEC were exposed to BAK-releasing materials. The lack of toxicity observed with BAK-
soaked balafilcon A lenses compared to BAK-soaked etafilcon A highlights the difference
in material properties and the ensuing difference in the mechanisms of BAK uptake and
release. Similar results have been observed previously with differential uptake and release
profiles of lens care solutions with different contact lens materials [42, 88].
In a dynamic system, if one were to compare with a static incubation in vitro model, two
different mechanisms may occur: (1) the in vitro cytotoxic effect may not be as pronounced
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Table 5.3: Effect of Tear Replenishment on Viability of Cells Exposed to BAK-soaked
Lenses for 2h.
No-Replenish† Replenish Test for with vs. without
Viability (%) Viability (%) replenishment, p value
balafilcon A-PBS 106± 5 100± 10 1.00
balafilcon A-BAK 86± 10 86± 5 0.99
etafilcon A-PBS 101± 14 113± 15 1.00
etafilcon A-BAK 80± 15 76± 18 0.54
n=3-4 mean ± standard deviation
† cells-contact lens system was fully immersed in solution for 2 hours.
compared to the static incubation model; this would be due to the dilution of the toxic
substance, not accumulating, and being washed away and removed by the TRS, as it
would be in tears, or (2) cytotoxicity may increase due to an increase in concentration
of the toxic substance being released into a much smaller residual tear liquid, especially
between the contact lens and the corneal cells, as it might be the case in tear film between
the epithelium and the contact lens. The latter mechanism was confirmed by results from
a 6h exposure to BAK-soaked etafilcon A whereby a statistically significant difference in
cell viability between replenishment vs. immersion model was observed. Interestingly, the
BAK-soaked balafilcon A lens did not act as a strong cytotoxic stimulus to cells, which
in turn made it difficult to identify differences between dynamic vs. static conditions.
The surface treatment of balafilcon A associated with the amphiphilicity of BAK is likely
responsible for the limited uptake (and then release of BAK) [42, 118], which makes this
BAK-lens combination of limited use when investigating the effects of tear replenishment
on cytotoxicity.
The experiments demonstrated that the implemented design to mimic tear replen-
ishment can deliver tear fluid to the stratified curved cornea models at a flow rate and
frequency that are similar to the human eye. Due to the static nature of the current in
vitro models, accumulation of the toxic agents in the culture medium may occur; thus,
the release profile may also be affected by the lack of replenishment. In the dynamic sys-
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tem presented with the tear replenishment, we demonstrated that replenishment can be
achieved without damaging the integrity of the stratified cell culture, that the replenished
conditions allowed the contact lenses to remain moist at all times without requiring im-
mersion in solution and that tear replenishment may have significant effect on measured
outcomes (here cytotoxicity).
5.5.3 TRS 2.0 - Drug Release Studies
The total drug uptake was calculated by measuring the remaining drug in the doping
solution and the drug doping solution. The stock solution concentration was measured at
123.4± 12.73µg/mL. It is important to note that the intended concentration of of doping
solution was 50µg/mL to match the prescribed dose of commercial eye-drops. However, the
reported drug amount by the supplier (Cayman Chemical, Ann Arbor, MI), which was used
as the basis for doping solution preparation, deemed to be incorrect when measuring the
stock solution concentration. Table 5.4 details the uptake results. While the concentration
of drug doping solution used for the tear replenishment experiments was comparable to
the release studies conducted in the previous chapter, the smaller doping solution volume
(1mL vs. 1.5mL) resulted in lower total drug available for uptake.
Table 5.4: Latanoprost Uptake Results into Three Commercial Contact Lens Materials
Contact Lens Material senofilcon A balafilcon A etafilcon A
Drug remaining in
doping solution (µg)
0.163± 0.048 0.178± 0.048 3.713± 0.846
Drug Uptake[µg/lens] 123.24 123.23 119.7
Uptake as a percentage
of available drug(%)
99.9 99.9 97.0
n=4, Mean ± Standard Deviation.
Lenses were soaked for 24 hours in 1mL of drug doping solution (123.4µg/mL). La-
tanoprost concentrations were measured using EIA.
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5.5.3.1 TRS v2.0 - Cell Viability
Cell viability studies were conducted to verify the integrity of the monolayer CCMs after
the drug release experiments. A significantly damaged cornea model would invalidate the
obtained release results. No visible damage to the cornea models was observed after 12h
of drug release experiments. This was confirmed by the viability assay (see Fig. 5.16).
The viability remained above 80% in all cases. No significant difference in viability was
observed among the lens materials (p > 0.4). While the viability was significantly less
under replenish conditions compared to no-replenish (p = 0.002), this was likely due to the
removal of loosely attached cells under dynamic flow conditions.
Figure 5.16: Effect of replenishment on corneal epithelial cell viability after 12 hour release
study with and without tear replenishment. Viability was measured by MTT assay and
is expressed as a percentage relative to in vitro CCM without replenishment. The results
represent the mean of three experiments (n=3 ± standard deviation). ∗ Significantly differ-
ent from no-replenish (p = 0.002). PBS, phosphate buffered-solution; BAK, benzalkonium
chloride
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5.5.3.2 TRS 2.0 - Latanoprost Apical Release
The apical release of the drug in the immersion model is defined as the amount of drug
released from the contact lens into the supernatant tear solution on the apical side of the
CCM (2.5mL). In the replenish model, the apical release is defined as the amount of
the drug released from the contact lens and collected in the supernatant drainage module
(12mL total volume). In the human eye, the drug released from an ophthalmic material
is first dissolved in the tear film with a limited volume before it diffuses through the
cornea. Comparing the apical release between replenish and immersion (no-replenish)
models allowed to gain a better understanding of the role that tear replenishment might
play in the human eye. The apical release results, as depicted in Fig. 5.17, showed that
significantly more latanoprost was dissolved in the supernatant in the immersion model
compared to the replenish model (p < 0.001), despite significantly smaller supernatant
liquid volume (2.5mL).
Furthermore, the apical release of latanoprost from etafilcon A was significantly higher
compared to the silicone hydrogels (p < 0.005), while there was no difference between
silicone hydrogels. This is consistent with the results from the previous chapter, where a
significantly higher amount of drug release was observed from high water content hydrogel
contact lenses such is the case for etafilcon A. This can be attributed to the bulk properties
of such materials and their relatively lower affinity towards highly hydrophobic compounds
such as latanoprost (see discussion).
5.5.3.3 TRS 2.0 - Release Results
Previous studies, presented in Chapter 4, proved the crucial role of live cells in the la-
tanoprost’s release from contact lens material and its diffusion through the cornea model.
Those studies were performed utilizing the immersion model. Drug release studies using
the TRS allowed us to gain an insight into the role of tear replenishment in drug release on
the basal side of the CCMs. The release results, as illustrated in Fig. 5.18, showed a linear
increase for all contact lens materials on the basal side in both immersion and replenish
models. The drug concentration on the basal side was similar in both models (p > 0.2),
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Figure 5.17: Effect of replenishment on the latanoprost release from three contact lens
materials in the monolayer CCMs. Lenses were soaked for 24 hours in drug solution
(123.4µg/mL) and then onlayed on the CCM for 12 hours. Aliquots were taken at the
end of the experiment from the apical side of the models without replenishment and from
the supernatant container for the replenished models. Then concentrations were measured
using EIA. # Significantly different from no-replenish model (p < 0.001). ∗Significantly
different from silicone hydrogels (p < 0.005). (n=3, mean ± standard deviation).
and the amount of latanaprost on the basal side was comparable to the prescribed dosage.
The different release profiles for the various contact lens materials were consistent with our
previous results [115].
5.5.4 TRS 2.0 - Discussion
This study aimed to assess the impact of modeling tear replenishment in vitro for drug
delivery studies from ophthalmic materials. The curved cornea models used in these ex-
periments have proven to be an effective platform for understanding biocompatibility of
contact lens material and lens cleaning solutions [78, 88, 119], which can further be used
with a dynamic replenishment model. The results highlight the importance of in vitro
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Figure 5.18: Effect of replenishment on the latanoprost release from three contact lens
materials through the CCMs on the basal side. Lenses were soaked for 24 hours in drug
solution (123µg/mL) and then onlayed on the CCM for 12 hours. Aliquots were taken at
specific times from the basal side and concentrations were measured using EIA. Daily dose
line represents the amount of the administered latanoprost for a glaucoma patient [27].
No significant difference was observed when comparing the latanoprost release from the
contact lens material and diffusion through the model to the basal side between replenish
(R) and no-replenish (NR, immersion) models (p > 0.2). ∗Release from etafilcon A in
no-replenish model was significantly higher at 12 h (p < 0.001). (n=3, Mean ± SD).
experimental cornea models allowing continuous replenishment at the surface of the cell
culture model for ocular drug delivery platforms in predicting the release profile and total
amount of intraocular drug diffusion under physiological conditions.
It is important to note that the drug release studies were performed on a monolayer
CCM rather than a stratified model. “Natural” cell sloughing in a dynamic replenished
environment is promoted, whereby in a stratified model, the underlying cell layer will
contribute to the regeneration of the superficial layer. However, in a monolayer model, due
to lack of a basal cell layer, this cannot happen, which will then result in a slightly reduced
viability. Thus, the observed decrease in viability, while statistically significant, is unlikely
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to be biologically significant for this study.
In case of drug release studies in a dynamic system, in comparison to the immersion in
vitro model, two different mechanisms may occur:
(1) the in vitro drug release may be elevated compared to the immersion model; this
would be due to the high solubility of the drug in the tear solution, and being washed away
and drained by the TRS, as it would be in tears through the lacrimal system, or
(2) the drug release may decrease due to the low solubility of the drug in the tear
solution resulting in lower concentration of the drug being released into a much smaller
residual tear liquid, especially between the contact lens and the corneal cells, as it might
be the case in the tear film between the epithelium and the contact lens.
The first mechanism may be the more dominant effect for hydrophilic ophthalmic drugs
while the second mechanism would be the predominant effect for hydrophobic compounds
such as latanoprost.
To provide a better comparison between the apical and and the basal release results at
12 hour, for the three commercial contact lenses, the results were normalized to the total
drug uptake into each lens material. This analysis is presented in Fig. 5.19, and shows
that the total drug release from silicone hydrogels (balafilcon A and senofilcon A) only
accounts for less than 2% in the replenish model and less than 3% in the immersion model.
The considerably high drug uptake and low drug release from the silicone hydrogel lenses
can be attributed to the higher affinity of the hydrophobic latanoprost to the hydrophobic
silicone hydrogel material (as would be the case with mechanism #2). Comparing the
results obtained using the two models showed the dominant effect of the hydrophobic-
hydrophobic interactions between the drug and the contact lens material resulting in a
reduced apical drug loss into the supernatant. Etafilcon A showed marginally less affinity
toward latanoprost when compared to the silicone hydrogels (see Table. 5.4). This resulted
in increased drug release on the apical and diffusion into the basal sides.
The significantly elevated latanoprost release on the apical side in the immersion model
is in spite of the considerably lower volume of supernatant fluid in the immersion model
(2.5mL vs. 12mL). This phenomenon can be understood more extensively if one were to
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consider the role that live cells play in hydrolyzing the prodrug. Due to the hydrophobicity
of the latanoprost, it may easily penetrate through the transcellular pathways into corneal
cells where it will be hydrolyzed into the free-acid form. The free-acid drug may leave
the cell membrane to either the apical or basal side. The limited post contact lens tear
film volume in the replenished model would inhibit the apical diffusion of the latanoprost
free-acid, while in the immersion model, the apical release would be promoted.
The latanoprost prodrug will be hydrolyzed upon entry into the cell due to the abun-
dance of esterase enzymes. While latanoprost may diffuse to either side of the cell layer,
the diffusion to the basal side may slightly decrease due to both the cell layer and the cell
culture membrane. This may explain the higher apical release in the no-replenish model.
While small differences might be justified by this mechanism, the significantly higher api-
cal release in etafilcon A requires further investigation. As discussed in section 3.4.5, the
highly hydrophobic rose bengal showed a significantly larger release. Latanoprost is also a
highly hydrophobic drug, that could easily release from etafilcon A and dissolve in the api-
cal solution in the ester form. This might explain the elevated apical release of latanoprost
from etafilcon A in no-replenish model. However as mentioned before, the EIA kit used in
these studies does not distinguish between the two drug forms and thus it will be difficult
to verify such a hypothesis.
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Figure 5.19: Effect of replenishment on the latanoprost release from three contact lens
materials on both basal and apical sides of the monolayer CCMs. The ratios for each
contact lens material were calculated based on the total drug uptake into each lens. No
significant difference was observed when comparing the latanoprost release from the contact
lens material and diffusion through the model to the basal side between replenish and no-
replenish model. However, etafilcon A showed more latanoprost release to the basal side
when compared to the two silicone hydrogel materials (p < 0.001). (n=3, Mean ± SD).
5.6 Conclusion
Through modeling the microfluidics of the tear replenishment in vitro, the TRS offers an
ocular drug delivery testing platform with a reliable and continuous replenishment of the
surface of the cell culture model that can contribute to a better understanding of corneal
cell-lens interactions in vitro. The latanoprost release studies, as discussed in chapter 4,
further confirmed the significant role that cells play in the release of an ocular prodrug from
a contact lens material. The results presented in this chapter demonstrated yet another
important role that a dynamic release model will have in predicting the amount of drug
that can be lost from a contact lens into tear film/lacrimal system.
The in vivo dynamic environment provided by tear replenishment impacts ocular in-
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flammation, drug delivery to the eye, and lens cleaning solution biocompatibility. While in
the current study, the tear replenishment system was used to investigate drug eluting con-
tact lenses, a more physiologically relevant in vitro ocular surface model can prove valuable
in biocompatibility studies for future drugs and ophthalmic materials. This model provides
one of the first approaches to study these effects in the presence of cells.
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Chapter 6
Contributions and Future Work
6.1 Scientific Contributions
A need for an organotypic culture system that can better model the physiological conditions
of the front of the eye was identified. This thesis aimed to answer three specific questions:
1. Does recreating the limited tear volume as well as the continuous tear replenishment
in studies of drug eluting contact lenses provide any unique insights to the release
mechanisms, that might be otherwise neglected or overlooked?
2. Does incorporating human corneal cells into an in vitro drug release model create a
meaningful impact in predicting the release of the drug from a contact lens material,
that could offset the high complexity and cost associated with operating a cell culture
facility?
3. And last but not least, if the answer to the questions above is yes, does integration of
a dynamic fluid exchange, modeling the tear replenishment in the human eye, with
a cell culture system, modeling the human cornea, allow investigation of release of
ophthalmic drugs from contact lens materials in a robust and reliable fashion?
The methods and results presented in Chapters 3, 4 and 5 of this thesis provided
compelling evidence and ample support to answer each of those questions positively. In
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relation to the questions this thesis aimed to answer, the specific contributions of this
research can be described as follows.
1. The Dynamic Drug Release Model (DDRM) is a novel testing platform, specifically
designed to test drug delivery contact lens. With its ability to test four contact lenses
simultaneously in a reusable and bio-inert chamber, the DDRM provides a unique,
cost-efficient and acellular drug release testing platform, capable of reproducing the
microfluidic environment of the ocular surface reliably. The systematic approach to
the design of the platform not only improves reliability but also enables the use of
this platform by researchers to perform studies on both commercially available and
custom-made contact lenses. Surrogate drug release experiments performed using
the DDRM validated the suitability of this testing platform for the study of release
from contact lenses. Using ophthalmic dyes as surrogate drugs with silicone and
conventional hydrogel lenses, this study is the first to directly compare drug release
under passive (fixed volume), passive with cells and dynamic (DDRM) conditions.
2. While neither stratified cornea models nor the idea of using latanoprost release from
a contact lens are novel, no ophthalmic drug release study had yet investigated the
impact that the presence of cells would have on drug release. The latanoprost release
study, published in PLOS ONE in 2014 [115], was performed using in vitro cell models
and demonstrated for the first time the significant role that cells play in drug delivery
study of ophthalmic materials, especially in the case of prodrugs.
3. The curved cornea model, developed by the MIBS lab, closely mimics the geometry
and physiology of the corneal epithelium, and is uniquely positioned to be integrated
into a tear replenishment system. The first prototype of the tear replenishment sys-
tem (TRS) was the first proof of concept which demonstrated that a curved stratified
corneal epithelial cell culture could (1) reliably be exposed to intermittent flow, mim-
icking the tear replenishment, and (2) wear a whole contact lens that would remain
hydrated -due to the presence of intermittent flow - for at least 6 hours. Results from
this study published in the Annals of Biomedical Engineering in 2014 also highlighted
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the fact that tear replenishment affects release and hence potential cytotoxicity of
ophthalmic solutions [119]. In a second iteration, the TRS was further improved to
allow for longer incubation time and separate collection of the supernatant/apical
drug release from each well. The new TRS design continues to preserve the air-liquid
interface of the stratified culture while mimicking tear replenishment conditions; this
is a novel and unique ocular cell model. Using contact lenses releasing latanoprost,
the TRS allowed to compare for the first time drug release mechanisms in the pres-
ence of cells under dynamic and static conditions and highlighted the rate-limiting
barrier created by the cells as well as the amount of drug that can be lost into the
supernatant/“tear film”.
6.2 Recommendations for Future Work
Recommendations relate to both the dynamic drug release model and the tear replenish-
ment system.
The goal of designing the dynamic drug release model was to provide a cost efficient,
open hardware/ open software instrument that can be adopted, modified and improved
by other researchers for the purpose of dynamic drug release studies from drug eluting
materials. While some may use commercially available contact lenses to study drug release,
others might synthesize a novel hydrogel. To address the needs of different research groups,
it is recommended that the design and the specifications of this system be published,
ensuring open access to all researchers.
Furthermore, this design can be modified into a standardized high-throughput system,
through which a large range of hydrogels and dye combinations can be screened rapidly to
identify the best possible candidates for drug eluting materials.
While characterization of drug delivery devices can benefit from a more realistic ocular
surface model, there is a much larger need to study the biocompatibility of ophthalmic
materials such as new contact lenses, or multipurpose solutions and their interactions,
or understanding the mechanism of corneal staining. It is recommended to employ the
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tear replenishment system in investigating these possible interactions to gain a better
understanding of the mechanisms involved in cell biocompatibility.
While the implemented experimental models took into consideration the microfluidic
environment of the ocular surface and cells, these models do not reproduce the mechanical
stimulation that is created from the movement of the eyelid through blinking. In an in vitro
model of the ocular surface, this mechanical stimulation would be important as it allows
some movement of the lens and thus promote tear exchange in the post-lens tear film and
it may also affect drug release. While it may be difficult to add a moving component to
simulate blinking in the TRS, it is recommended that efforts be undertaken to assess the
current exchange of fluid between the lens and the curved corneal epithelial cell culture
and further to improve the current design to promote fluid exchange at the back of the
lens.
Most in vitro studies have taken place under static conditions. The TRS also offers
new possibilities to investigate the effect of a dynamic environment in wound healing,
inflammation and infection.
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Appendix B: Fractional Solute
Release Ratio Graphs
When studying drug release from polymeric devices under perfect sink condition, it is
common to use fractional solute release ratio,Mt/M∞. The perfect sink condition allows
extraction of most of the solute from the polymer network. Therefore, normalizing the
release over time to the maximum total release will enable an easier comparison among the
lens materials.
In the small sink model (fixed volume model) used in this research, only a limited
amount of drug is released from contact lens material over the course of experiments (48h).
Thus, the release results were normalized to the uptake by each lens. In this appendix the
fractional solute release ratio graphs are presented. It must be noted that these graphs
do not replicate the release behavior of tested contact lens materials under perfect sink
conditions.
138
Figure B.1: Fractional solute release ratio of fluorescein sodium in fixed volume release
model
Figure B.2: Fractional solute release ratio of rhodamine B in fixed volume release model
139
Figure B.3: Fractional solute release ratio of rose bengal in fixed volume release model
140
Appendix C: Release of Surrogate
Drugs
In this appendix, the release and release to uptake ratio graphs for fixed volume model as
well as the cell model for 48h are presented and compared to the 24h release in dynamic
drug release model.
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